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ABSTRACT 
Background: Despite the improved screening and treatment modalities, lung 
cancer is the second leading cause of cancer and accounts for 27% of all cancer deaths in 
the United States. Survivors of lung cancer experience physical, social, and particularly 
psychological challenges. Lung cancer stigma is a formidable challenge for survivors of 
lung cancer that complicates their physical, psychological and social well-being. 
The Cataldo Lung Cancer Stigma Scale is the first instrument adapted to measure 
lung cancer stigma. This instrument was adapted from Berger’s HIV Stigma Scale. HIV 
stigma and lung cancer stigma share similarities. These health-related stigmas reflect 
behaviors that are associated with the development of a debilitating disease and where 
those who partake in this behavior bear responsibility for the development of the disease. 
In previous studies, the CLCSS was reported to have very good reliability and construct 
validity. However, those studies lacked adequate African American representation. 
African Americans experience a significant disparity in lung cancer incidence and 
survival rates. In South Carolina, African American men have a higher incidence and 
lower survival rate in comparison to their Caucasian counterparts, whereas African 
American women have a lower incidence and lower survival rate compared to Caucasian 
women. This disparity is concerning and warrants investigation of the possible factors 
that contribute to the disparate rate. The goal of this research is to enhance existing 
knowledge of stigma and its effect on individuals in South Carolina living with a lung 
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cancer diagnosis with equal representation of African American and Caucasian survivors 
of lung cancer. 
 Methods: This multiple-method study evaluated the reliability and construct 
validity of the CLCSS among a purposive sample of survivors of lung cancer in South 
Carolina. Secondly, lung cancer stigma, depression, and QOL were evaluated by the 
calculation and comparison of means among demographic characteristics. Thirdly, the 
relationship between lung cancer stigma and race was evaluated, adjusting for 
demographic characteristics. And lastly, the experience of living with lung cancer and the 
interpretation of the CLCSS were explored among African American participants. 
Findings: Participants (n = 56) included 30 Caucasian and 26 African American 
survivors of lung cancer recruited from a cancer registry of an American College of 
Surgeons–accredited program, a support club for survivors of lung cancer, and a private 
ambulatory oncology practice, all near Columbia, South Carolina. Among the 26 African 
American participants, quantitative analysis indicated a moderate level of lung cancer 
stigma, a moderately high level of depressive symptoms, and quality of life (QOL). 
Depressive symptoms were positively associated to lung cancer stigma, and QOL was 
negatively associated to lung cancer stigma. Qualitative analysis revealed social isolation 
secondary to physical limitations, regrets relative to cigarette smoking, and unfair 
treatment of insurance providers and employers.  
 Conclusions: Lung cancer stigma adversely impacts overall QOL of survivors of 
lung cancer. It is imperative that health professionals acknowledge and are aware of the 
negative influences lung cancer stigma imposes. A holistic clinical evaluation 
encompassing physical, psychological, and social well-being is needed to identify and 
viii 
address the needs of survivors of lung cancer relative to lung cancer stigma and the 
impact it may have on overall QOL. Additional research is needed to assist with the 
development of tailored interventions that will aid in mitigating the harmful effects of 
lung cancer stigma. 
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CHAPTER 1: INTRODUCTION 
History and Overview of Lung Cancer 
Lung cancer is the second-leading cause of cancer and accounts for 27% of all 
cancer deaths in the United States (American Cancer Society [ACS], 2019; American 
Lung Association [ALA], 2019). The ACS estimated over 225,000 new cases of lung 
cancer would be diagnosed in 2019, with more than 142,000 deaths nationally (ACS, 
2019). The incidence of lung cancer is slowly declining due to the decrease in tobacco 
usage. In addition, the survival rates are increasing thanks to improved screening 
practices and treatment modalities (ACS, 2019; de Moor et al., 2013). The 5-year relative 
survival rate for lung cancer is up from 13% for 1987–1989 to 20% for 2008–2014 (ACS, 
2019). If diagnosis precedes metastasis, the 5-year relative survival rate increases to 56% 
(ACS, 2019).  
The Institute of Medicine (2013), or IOM, reported that 14 million cancer 
survivors lived in the United States in 2012. By 2022, this number will increase to 18 
million (IOM, 2013). This population will encompass a growing number of lung cancer 
survivors, whose survival rate is defined by the time from diagnosis until the end of life 
(IOM & NRC, 2006). It is imperative for researchers to identify, examine, and gain a 
better understanding of the potential and current issues that cancer survivors encounter 
over the course of their disease. This is especially crucial for lung cancer survivors in 
light of the particular challenges they face.  
 Lung cancer survivors experience significant physical symptom burden, 
2 
psychological distresses, and social challenges alongside their disease process and 
treatment options (Brown-Johnson et al., 2015; Chambers et al., 2012; Chambers, Baade 
et al., 2015; Chapple, Ziebland, & McPherson, 2004; Gonzales & Jacobsen, 2012; 
Gonzalez et al., 2015; Hamann et al., 2014; Houlihan & Tyson, 2012). The presence of 
pain, breathlessness, loss of appetite, fatigue, insomnia, and difficulty swallowing are 
common among lung cancer survivors and adversely affect their overall quality of life 
(Fiteni et al., 2016; Houlihan & Tyson, 2012; Rauma, Sintonen, Räsänen, Salo, & Ilonen, 
2015). These physical symptoms also affect the ability to successfully master normal day-
to-day activities of living and alter social well-being, which is important for overall 
health (World Health Organization, 2017). Lung cancer survivors also experience a 
higher level of psychological distress such as depression and anxiety (Brown-Johnson, 
Brodsky, & Cataldo, 2014; Cataldo, Jahan, & Pongquan, 2012; Chambers et al., 2012; 
Chambers, Baade et al., 2015; Chapple et al., 2004; Gonzales & Jacobsen, 2012; Hamann 
et al., 2014). These psychological distresses may be exacerbated by perceptions and 
actions of others related to a lung cancer diagnosis.  
Health-related stigma affects many aspects of life for individuals living with a 
disease such as lung cancer (ALA, 2014; Cataldo et al., 2012; Chapple et al., 2004; 
Hamann et al., 2014; Gonzalez & Jacobsen, 2012; Lehto, 2014). One example of a 
health-related stigma is lung cancer stigma, which is negatively associated with quality of 
life (QOL) and survival rates of individuals living with lung cancer (Brown-Johnson et 
al., 2014; Cataldo et al., 2012; Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011; 
Chambers, Baade et al., 2015; Rauma et al., 2015; Rowland et al., 2014).  
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History and Background of Lung Cancer Stigma 
 Stigma is an undesirable stereotype that places an individual in a group that is 
devalued because of a particular attribute (Goffman, 1963). A health-related stigma is the 
perception of possessing a trait that produces an unfavorable outcome (Berger, Ferrans, & 
Lashley, 2001). In the case of lung cancer, the trait is the behavior of cigarette smoking, 
which leads to the unfavorable outcome of a lung cancer diagnosis (Cataldo et al., 2012). 
Lung cancer stigma is a complex concept intertwined with cigarette smoking and has a 
widespread effect on the physical, psychological, and social well-being of lung cancer 
survivors (Brown-Johnson et al., 2014; Cataldo et al., 2012; Chambers, Baade et al., 
2015; Criswell, Owen, Thornton, & Stanton, 2016; Gonzalez & Jacobsen, 2012; Hamann 
et al., 2014).  
Cigarette smoking and lung cancer have a well-established relationship. In 1964, 
the U.S. Surgeon General’s advisory report, Smoking and Health, provided 
groundbreaking information for medical professionals, public health officials, and the 
general public on the link between cigarette smoking and the development of chronic 
diseases (U.S. Department of Health and Human Services Public Health Office of the 
Surgeon General [OSG], 2014). Subsequent Surgeon General reports further cemented 
cigarette smoking as an environmental health hazard (OSG, 2014). These reports 
prompted public health initiatives, education, and federal and state policies that focused 
on decreasing tobacco usage and eliminated smoking from public places in the United 
States (Bayer, 2008). Although these well-intentioned public health efforts were initiated 
to eliminate tobacco usage, they changed societal views about both cigarette smoking and 
those who smoke (Bayer, 2008). These initiatives prompted new rhetoric from tobacco 
4 
companies, labeling smoking as a “choice.” This message implicitly defended cigarette 
manufacturers’ profits and thrust the responsibility for cigarette smoking—along with the 
development of chronic debilitating diseases linked to smoking, including lung cancer—
onto individuals (ALA, 2014).   
In 1988, the U.S. Surgeon General reported that nicotine and cigarette additives 
harbor addictive properties. Nonetheless, stigmatization continues to occur for 
individuals who currently smoke or previously smoked cigarettes. Even though cigarette 
smoking also contributes to the development of other types of cancer—including bladder, 
colorectal, kidney, and liver cancer—cigarette smokers are deemed responsible for their 
“choice” and are most commonly blamed for the development of lung cancer (ALA, 
2014; Daher, 2012; Lebel et al., 2013). The interrelated dimensions of cigarette smoking 
and lung cancer result in a layered effect of stigma for lung cancer survivors and can have 
a significant, far-reaching impact on the lives of lung cancer survivors (Chambers, Baade 
et al., 2015; Criswell et al., 2016; Webb & McDonnell, 2018).  
 Lung cancer researchers, governmental agencies, and nonprofit organizations 
acknowledge the presence of lung cancer stigma and its impact on lung cancer survivors 
(Cataldo et al., 2012; Chapple et al., 2004; Lehto, 2014; Hamann et al., 2014; Gonzalez & 
Jacobsen, 2012). The number of studies evaluating lung cancer stigma has increased 
since 2011. However, few research studies measure lung cancer stigma and its 
association with QOL measures (physical, psychological, and social well-being) in a 
population that experiences a proportionately greater rate of lung cancer incidence and 
mortality than other groups: African Americans.  
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For the year of 2016, the ACS estimated more than 24,000 lung cancer diagnoses 
were made among African Americans, comprising 13% of all cancer diagnosis for this 
population, with more than 17,000 deaths resulting from the disease (ACS, 2016). The 5-
year relative survival rate for lung cancer is lower in African Americans (14%) compared 
to the rate among Caucasians (18%) (ACS, 2016). A 2018 report by the Centers for 
Disease Control and Prevention (CDC) ranked South Carolina 16th in lung cancer 
incidence. Among those with lung cancer in the state, African American males display a 
higher age-adjusted incidence and lower survival rate (88% and 13.4%, respectively) than 
Caucasian males (78.8% and 15.5%), while African American women have a lower age-
adjusted incidence and survival rate (39.5% and 19.1%, respectively) than Caucasian 
women (56.1% and 21.6%) (CDC, 2018). This disparity among African Americans in 
general, and in South Carolina in particular, is disconcerting.  
There are factors to consider given this cancer disparity between African 
Americans and those of other races/ethnicities in South Carolina. Evidence from research 
indicates African American cancer survivors experience a higher level of depressive 
symptoms, which negatively influence overall QOL (Traeger, Cannon, Pirl, & Park, 
2013). Additional inquiry is warranted to gain a better understanding of stigma and to 
evaluate its effect on psychological challenges as well as on overall QOL. An equal 
representation of African American and Caucasian lung cancer survivors will allow 
examination of lung cancer stigma, depressive symptoms, and QOL outcomes, especially 
as they may differ between populations. This research will expand existing knowledge of 
lung cancer stigma and may assist with tailored interventions to improve QOL and 
survival rates among lung cancer survivors, particularly African Americans.  
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Specific Aims and Hypotheses 
The Cataldo Lung Cancer Stigma Scale (CLCSS), adapted in 2011 from Berger’s 
HIV Stigma Scale, is the first validated health-related stigma instrument specifically 
designed to evaluate those living with lung cancer (Cataldo et al., 2011). CLCSS 
evaluates perceived stigma using four domains: stigma and shame, discrimination, social 
isolation, and smoking. However, this instrument has not been evaluated for readability 
and content validity among African American survivors of lung cancer. The purpose of 
this dissertation study is to evaluate lung cancer stigma and its association with 
depressive symptoms and QOL outcome measures among survivors of lung cancer, with 
equal representation of Caucasians and African Americans living with a lung cancer 
diagnosis in South Carolina. The goal of this research is to enhance existing knowledge 
of stigma and its effect on individuals in South Carolina living with a lung cancer 
diagnosis. The specific aims of this dissertation study are as follows:  
1. Evaluate reliability and construct validity of the Cataldo Lung Cancer Stigma 
Scale on a purposive sample of Caucasians and African Americans in South 
Carolina with a history of lung cancer, stages Ia–IV.  
2. Calculate and compare levels of stigma, depression, and QOL for each race, 
gender, and smoking status. 
3. Evaluate the relationship between lung cancer stigma and race, adjusting for 
all other demographic variables.  
4. Explore the experiences of African American lung cancer survivors relative to 
stigma and the interpretation of the CLCSS. 
The following hypotheses will be tested: 
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1. The CLCSS will demonstrate internal consistency among this population of 
lung cancer survivors, with a Cronbach’s alpha of greater than 0.7. 
2. There will be a statistically significant positive association between lung 
cancer stigma and depressive symptoms. 
3. There will be a statistically significant negative association between lung 
cancer stigma and quality of life.  
4. There will be a statistically positive relationship between lung cancer stigma 
and race after adjusting for other demographic variables.  
Theoretical Framework 
 Cataldo and colleagues developed the Lung Cancer Stigma Model based on 
Berger and colleagues’ 2001 HIV Stigma Model (Berger et al., 2001; Cataldo et al., 
2011). Both models led to the development of scales to measure stigma in the health-
related population each model addressed. Lung cancer and HIV stigma share some 
common threads. Both originate from the perspective that the individual is responsible 
for the development of the disease due to individual choices and behaviors. Both are 
therefore considered to be self-inflicted. Studies indicate that individuals with HIV and 
lung cancer share tremendous symptom burden, high levels of anxiety and depression, 
and social challenges such as isolation and rejection related to their diagnoses (Buseh, 
Kelber, Hewitt, Stevens, & Park, 2006; Chambers et al., 2012; Levi-Minzi & Surratt, 
2014). The perspective of those around them influences survivors of lung cancer. These 
influences may alter different aspects of their lives over the span of the disease. For this 
reason, it is important that a conceptual model address the various factors that may 
influence the experiences the survivor may have. 
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 The Lung Cancer Stigma Model consists of three identified dimensions: (1) 
precursors, (2) perceptions, and (3) responses (see Figure 1.1; Brown-Johnson et al., 
2015; Cataldo et al., 2011). These dimensions represent the perceptions, internalized 
feelings, and experiences of lung cancer survivors relative to stigma. These stages usually 
occur sequentially. The precursor stage involves the survivors’ awareness of societal 
views toward a lung cancer diagnosis and their personal views of having the disease. This 
stage encompasses survivors’ awareness of the stigma of cigarette smoking and the 
knowledge that smoking may be a contributing factor in the development of lung cancer. 
The perceptions stage encompasses perceived stigma of having lung cancer. At this point, 
lung cancer survivors perceive the actual or potential negative appraisal from others 
resulting from their diagnosis. The negative appraisal from others can lead to social 
rejection and discrimination. There is potential for identity change of the survivor as 
result of the negative appraisal of others. This can, in turn, result in shame and blame 
related to smoking and the development of the cancer. The consequences of stigma, as 
well as coping mechanisms, are addressed in the response stage. Perceived stigma can 
directly or indirectly influence dimensions of QOL for survivors (Brown-Johnson et al., 
2014). This includes physical, psychological, and social well-being. Physical well-being 
includes symptom burden for the lung cancer survivor. Psychological well-being 
encompasses, but is not limited to, anxiety, depression, and coping (Gonzalez & 
Jacobsen, 2012). Social well-being includes challenges such as withdrawal and 
avoidance. Within the response stage, positive results are possible. For example, there is 
a chance that the experience of stigma could lead to a therapeutic result or a change in 
priorities or worldview (Hamann et al., 2014). 
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Proposed Conceptual Model 
 This dissertation will be guided by the principal investigator’s adapted model of 
the Lung Cancer Stigma Model (see Figure 1.2). This adapted model will provide the 
framework for examining the association among lung cancer stigma, depression, and 
QOL. As noted, the survivor of lung cancer may perceive societal attitudes relative to 
smoking and a lung cancer diagnosis. The survivor may also be aware of potential or 
actual behaviors exhibited by others and feelings that may occur because of this 
perception. This may lead to feelings that negatively affect their identity-stigma and 
shame. The perceptions and feelings of the survivor may also be associated with 
depression and lower QOL, thereby affecting the chance of survival.  
Research Design, Methods, and Data Analysis 
Research Design 
 To address the purpose and specific aims, quantitative and qualitative methods 
were used. Correlational analysis was used to analyze and quantify relationships among 
lung cancer stigma, depression, and QOL measures. To examine the relationship between 
lung cancer stigma and race, a generalized linear model was used. All demographic 
characteristics were assessed for statistically significant relationships with lung cancer 
stigma. Interviews were conducted with African American participants to ascertain their 
experiences regarding lung cancer stigma and their interpretation of the CLCSS.  
Sample 
 The institutional review boards (IRBs) of the University of South Carolina (USC) 
and Palmetto Health (PH) in Columbia, South Carolina, approved this research. The PH 
cancer registry of approximately 500 potential participants was used for recruitment. 
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Equal percentages of Caucasian and African American survivors were initially targeted 
for recruitment. A power analysis was conducted to determine a sufficient sample for an 
alpha cutpoint of .05, a power of .80, and a large effect size of .35 (Grove, Burns, & 
Gray, 2013). This analysis indicated a desired sample size of 52, with 26 Caucasians and 
26 African Americans. With Pearson correlation analysis, the total sample size of 13 is 
required to determine whether a correlation coefficient differs from zero with an alpha of 
0.05 and beta of 0.2 (Polit & Beck, 2008). To be eligible for enrollment in this study, an 
individual must have (1) been 21 years of age or older; (2) had a personal history of lung 
cancer; (3) been able to speak and read English; and (4) resided in South Carolina.  
Recruitment 
 The primary recruitment method was an IRB-approved recruitment letter and 
flyer, indicating the purpose and procedure of the study; the flyer was mailed to potential 
participants who were identified by a cancer data system from PH hospitals located in 
Columbia, South Carolina. Palmetto Health Cancer Centers are American College of 
Surgeons–accredited cancer programs where patient tracking is maintained by a cancer 
registry. Over a 4-month time period, a letter and flyer were sent to 500 survivors with a 
lung cancer diagnosis. A follow-up telephone call was made within 1–2 weeks. Potential 
participants had the option of having the surveys mailed to them, administered verbally 
via telephone, or administered in person by the principal investigator (PI) at a convenient 
location. The secondary recruitment method was face-to-face meeting with survivors in 
attendance at a Breathe Easier Club meeting held monthly over a 2-month period. The 
Breathe Easier Club is a support group for lung cancer survivors in Greater Columbia, 
South Carolina. The third and final recruitment strategy was placement of recruitment 
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flyers at strategic areas of South Carolina Oncology Associates, an ambulatory cancer 
care treatment center. Face-to-face introductions between lung cancer survivors and the 
PI were made during the survivors’ appointment visits, with the assistance of oncology 
nurses. Any participant who completed the survey and/or an interview was given an 
appreciation gift (a gift card to a local retail store). 
Measures 
 The first instrument used was the CLCSS. This 31-item, 4-point Likert scale 
evaluates stigma. The original psychometric testing was conducted in 2011 (Cataldo et 
al., 2011). Construct validity was determined by exploratory factor analysis, which 
identified the four domains: stigma and shame, social isolation, discrimination, and 
smoking. Construct validity was supported by known relationships among related 
constructs of self-esteem, depression, social support, and social conflict (Cataldo et al. 
2011). The developer of the CLCSS has given permission for our use of this instrument. 
(See Appendix A for a sample of the scale and permission for use of the scale).  
 The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item 
self-report scale (Radloff, 1977). This instrument assesses eight domains of depression: 
depressed mood, feelings of guilt, feelings of worthlessness, feelings of helplessness, 
feelings of hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. 
This scale has been shown to be reliable with clinical and general populations of males 
and females, and both Caucasians and African Americans. It has a high internal 
consistency ranging from 0.85 to 0.90 (Radloff, 1977). This instrument is in the public 
domain. (See Appendix B.)  
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 The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30) measures QOL in individuals with a cancer 
diagnosis (Aaronson et al., 1993). There are supplements for specific cancer types that 
accompany the original instrument. For our study, a lung cancer supplement of 13 
questions was added to the original survey. This scale was tested on lung cancer patients 
(n = 110) and yielded an acceptable internal consistency of 0.70 (Nicklasson & Bergman, 
2007). Criterion validity was supported by correlation with clinical parameters that 
addressed all domains of the instrument (Nicklasson & Bergman, 2007). This instrument 
is in the public domain. (See Appendix C.)  
The primary investigator developed a demographic form to collect information 
about each participant that included gender, age, race, annual household income, year of 
lung cancer diagnosis/staging of cancer, self-report of health status, smoking status, 
educational attainment level, and employment data. (See Appendix D.)  
Analysis 
The study variables—stigma, depression, and QOL—were summarized using 
frequencies (for categorical variables) or means with standard deviations (for continuous 
variables) (DePoy & Gitlin, 2011). Demographic characteristics, lung cancer stigma, 
depression, and QOL were tested for bivariate associations using t-tests for continuous 
variables (Grove et al., 2013). Relationships between the demographic characteristics and 
outcome variables were tested using the independent t-test and analysis of variance 
(ANOVA). Pearson’s correlations were used to assess associations between continuous 
demographic variables and the main outcome variables. Statistical analysis was computed 
via SPSS® version 25. Cronbach’s alpha was used to determine internal consistency. A 
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value of 0.7 is considered acceptable (Grove et al., 2013). The CLCSS had established 
construct validity from the original psychometric testing. For this study, it was imperative 
to determine if the instrument maintains construct validity. Depression and QOL were the 
constructs chosen to assess bivariate correlation with stigma. The desired goal was to 
obtain correlations with large strength among constructs, establishing strong associations 
and validating the direction of the relationship between the variables as well as the degree 
of variance (Grove et al., 2013).  
 To determine the relationship between lung cancer stigma and race, a generalized 
linear model was used. Independent variables/demographics were evaluated for 
statistically significant relationships with stigma and race by utilizing a bivariate analysis 
to determine significance. The final model was tested by utilizing any demographic 
variable that met the requirement of a having a statistically significant relationship with 
race and lung cancer stigma.  
 The CLCSS has not been evaluated specifically among African American lung 
cancer survivors for cultural considerations and construct validity using an adequate 
sample size. In order to address this deficit, the PI conducted individual interviews, using 
semi-structured guide with 10 African American participants who had previously 
completed the study surveys. The goal of these interviews was to understand how the 
participants viewed each statement and to ascertain if the CLCSS questions were 
appropriate concerning language and their ability to capture the essence of stigma.  
Overview of Manuscripts and Target Journals 
 Lung cancer stigma affects survivors, family members, and health professionals. 
Specifically, stigma affects the diagnosis of lung cancer, treatment modalities, survival 
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rates, and QOL. Articles generated by this study will be published in journals whose 
readership consists of health-care professionals treating and caring for an individual with 
or recovering from this disease.  
 The first manuscript is a scoping literature review of lung cancer stigma. The 
review synthesized quantitative and qualitative studies to help conceptualize lung cancer 
stigma, identify instruments used to evaluate and quantify this stigma, and determine 
gaps in the literature or areas needing further investigation. This manuscript has been 
accepted for publication in Oncology Nursing Forum, with an anticipated publication of 
July 2019.  
 The next manuscript discusses our study’s mixed methods approach involving 
results from African American participants. The manuscript includes the qualitative 
component of the data investigating African Americans’ perspectives of lung cancer 
stigma and the interpretation of the CLCSS. The quantitative data analysis will correlate 
stigma, depression, and global health in this sample. This manuscript will be submitted to 
the Journal of Psychosocial Oncology in May 2019.  
 The third manuscript will consist of results of the entire sample evaluating the 
correlations of stigma, depression, and QOL, comparing these relationships for African 
American and Caucasian lung cancer survivors. That evaluation will include regression 
analysis to assess the relationship between stigma and race, adjusting for other 
demographic characteristics. That third manuscript will be submitted to the European 
Journal of Oncology Nursing in May 2019.   
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Figure 1.1 Lung Cancer Stigma Model (Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 
2011). 
 
 
Precursors 
Perceptions of societal attitudes toward smokers and people with lung cancer 
Knowledge of self as having lung cancer 
Perceived Stigma of Having Lung Cancer (aware of actual or potential) 
Social disqualification (social isolation subscale) 
Limited opportunities (discrimination subscale) 
Negative change in identity (stigma and shame, and smoking subscales) 
 
Possible Responses 
Physical reactions 
Physical symptom burden 
Emotional reactions 
Change in self-concept 
Psychosocial symptom burden 
Use of techniques to avoid or minimize stigma (e.g., information control, 
avoidance and  withdrawal, tension reduction) 
Redefined worldview or priorities 
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Figure 1.2 Proposed Lung Cancer Stigma Model.  
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CHAPTER 2: 
EXPLORING STIGMA AMONG LUNG CANCER SURVIVORS:  
A SCOPING LITERATURE REVIEW1
                                                 
1 Webb, L.A., McDonnell, K. K., Adams, S. A., Davis, R. E., & Felder, T. M. Accepted by Oncology 
Nursing Forum. Reprinted here with permission of publisher, 2/14/2019. Note that ONF holds rights as the 
original publisher of the data in this chapter. See Appendix E. 
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Abstract 
Problem Identification:  
Lung cancer survivors face many challenges that affect their quality of life and survival. 
A growing concern is the layered effect of stigma related to both cigarette smoking and 
the perceived life-threatening diagnosis of lung cancer. This experience may affect lung 
cancer survivors’ physical, psychological, and social well-being, thus negatively 
influencing their quality of life.  
Literature Search: 
CINAHL, PubMed, PsycINFO, and Web of Science were searched from the period of 
January 2000 through August 2017, using combinations of four keywords: lung cancer, 
lung neoplasm, stigma, and smoking.  
Data Evaluation: 
Extracted data include research aim(s), design, method, analytical approach, sample size, 
gender, ethnicity/race, setting, stigma measure, smoking status, and major results. 
Synthesis:  
Of 163 studies initially identified, 30 studies (7 qualitative, 10 quantitative, 1 mixed 
method, 1 systematic review, and 1 meta-analysis) were included. An evidence table 
presents studies alphabetically in chronologic order according to publication year. 
Quantitative studies were analyzed by statistically relevant results, whereas thematic 
analysis was used to evaluate qualitative studies. Instruments assessing stigma in the 
review are listed alphabetically.  
Conclusions: 
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These studies affirm that lung cancer stigma is associated with feelings of self-blame, 
anger, regret, and guilt, and with perceptions of shame, discrimination, and blame. These 
feelings and perceptions may negatively affect the overall well-being of lung cancer 
survivors. This review offers an understanding of lung cancer stigma and provides 
substantial data that may lead both to the development of intervention(s) that aim to 
reduce the consequences of stigma and to improved overall quality of life for lung cancer 
survivors.           
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Background 
Lung cancer is the second-leading cause of cancer among adults, accounting for 
27% of all cancer deaths in the United States (American Cancer Society [ACS], 2018; 
American Lung Association [ALA], 2018). Due to advances in screening practices, early 
detection, and improved treatments, lung cancer survival rates continue to improve (ACS, 
2018; de Moor et al., 2013). In 2018, the 1-year and 5-year survival rates for lung cancer 
were 50% and 18%, respectively, up from 37% and 15% in 2013 (ACS, 2018; ALA, 
2018).  
 The Institute of Medicine (2013) reported that 14 million cancer survivors lived in 
the United States in 2012, a number projected to rise to 18 million by 2022. The 
increasing cancer survival rates, including the rising lung cancer survival rates—defined 
as the average time between diagnosis and end of life—warrant examination to 
understand the challenges these survivors face, especially stigma.  
Stigma is “an undesirable stereotype leading people to reduce the bearer from a 
whole and usual person to a tainted, discounted one” (Goffman, 1963, p. 3). Health-
related stigma is the perception of possessing a trait that produces an unfavorable health 
outcome. For lung cancer, the health-related stigma is a perception that individuals 
diagnosed with lung cancer must be tobacco users, because tobacco use is the leading 
cause of lung cancer (Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011). Today, 
cigarette smoking is viewed as a poor life choice, and individuals who make this choice 
are perceived as being responsible for their lung cancer diagnosis (Cataldo et al., 2011; 
Lehto, 2014). This perception grew out of the U.S. Surgeon General’s 1964 report 
Smoking and Health, which heightened public awareness of the effects of tobacco use 
and its link to chronic illnesses. Subsequent Surgeon Generals have validated that 
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groundbreaking finding and revealed more concerns regarding tobacco use that affect 
non-smokers (U.S. Department of Health and Human Services Public Health Office of 
the Surgeon General, 2014). Now-pervasive antismoking initiatives have denormalized 
smoking, leading to smokers being blamed for diseases with which their behavior is 
linked (Bayer, 2008; Gielen & Green, 2015; Peretti-Watel, Legleye, Guignard, & Beck, 
2014).  
Lung cancer survivors experience higher levels of psychological distress 
compared to other cancer survivors (Brown-Johnson et al., 2015; Chambers, Baade et al., 
2012; Chambers, Morris et al., 2015; Chapple, Ziebland, & McPherson, 2004; Gonzalez 
& Jacobsen, 2012; Hamann et al., 2014). Stigma is thought to lead to further 
psychological distress and social isolation, and to negative effects on physical and 
functional well-being (Brown-Johnson et al., 2015; Cataldo et al., 2011; Chambers et al., 
2012; Chambers, Baade et al., 2015; Gonzalez & Jacobsen, 2012; Hamann et al., 2014).  
Although there is acknowledgement of the negative ramifications of lung cancer 
stigma, there are scant studies addressing possible interventions for oncology health 
professionals to assist with alleviating the significant effect stigma has on lung cancer 
survivors. One of the first studies that contributed to the conceptualization of lung cancer 
stigma dates back 14 years (Chapple et al., 2004). To date, existing research has 
evaluated lung cancer stigma and its impact on physical, social, and psychological 
challenges experienced by survivors. Examination of existing literature will not only 
assist with enhancing the conceptualization of lung cancer stigma, but also identify gaps 
and provide suggestions for oncology practice and future research. The authors chose a 
scoping review to provide this direction. This review captures emerging knowledge, 
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identifies areas where scientific advancement is needed, and seeks to contribute to the 
future development of interventions that will mitigate stigma-induced distresses and 
improve survivors’ quality of life (QOL).  
Methods 
 Using the process delineated by Arksey and O’Malley (2005), a scoping review 
was conducted of the stigma experience among lung cancer survivors. The five-step 
process involved (1) identifying the research question; (2) identifying relevant studies; 
(3) selecting the studies; (4) charting the data; and (5) summarizing the data and reporting 
results. Following this process, pertinent research questions were identified and included: 
(1) How is lung cancer stigma measured?; (2) How can we fully describe the stigma lung 
cancer survivors face?; and (3) How does lung cancer stigma affect survivors’ overall 
QOL? Existing research was delineated by the measures of lung cancer stigma, the scope 
and depth of stigma among adult lung cancer survivors, and the impact stigma has on 
QOL. Existing research was categorized and summarized. Clarification of the conceptual 
definition and identification of research gaps were reported, and suggestions of future 
paths for research were recommended (Peters et al., 2015). 
Identification of Relevant Research Studies 
CINAHL, PubMed, PsycINFO, and Web of Science were used to identify research 
studies published between January 2000 and August 2017. Searches included four 
keywords in the following combinations:  
• Lung neoplasm AND stigma 
• Lung cancer AND stigma AND smoking 
• Lung neoplasm AND stigma AND smoking 
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• Lung cancer AND stigma OR smoking  
• Lung neoplasm AND stigma OR smoking 
 Keywords could appear in the title, abstract, and/or body of the article. For an 
article to be included, it had to be published in English in a peer-reviewed journal. The 
inclusion criteria also required that sample participants be age 18 or older and survivors 
of small-cell or non-small-cell lung cancer. Studies that did not consider stigma 
associated with lung cancer as one of its aims were excluded from the review. Studies 
included must have examined stigma or an outcome variable associated with lung cancer 
stigma, such as—but not limited to—smoking status, depressive symptoms, and QOL. 
Previous studies using either qualitative and quantitative research methodologies were 
included. 
 A search across all four databases yielded 163 articles (see Figure 2.1). Duplicate 
articles (n = 114) and non-research articles, commentary articles, and theoretical reviews 
(n = 48) were excluded. After making these exclusions, 30 relevant publications remained 
and were included in our review (see Table 2.1). Existing research was delineated, 
categorized, and summarized by the study methods, measures of lung cancer stigma, the 
scope and depth of stigma among adult lung cancer survivors, and the impact stigma has 
on QOL.  
Data Extraction, Analysis, and Synthesis 
Evaluated data included research aim(s), design, method, analytical approach, 
sample size, gender, ethnicity/race, setting, stigma measure, smoking status, and major 
results. Studies aimed to define internal, external, and perceived stigma and to understand 
the health consequences and QOL impact stigma has on lung cancer survivors. Evidence 
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tables were developed to organize quantitative and qualitative data chronologically and in 
alphabetic order relative to date of publication. Instruments measuring stigma were 
organized in alphabetical order.  
Results 
Overview of Studies Reviewed 
The four earliest studies were published between 2004 and 2009; the remaining 
26 were published since 2011. A majority of studies (n = 17) were conducted in the 
United States. Others took place in Australia (n = 3), the United Kingdom (n = 3), 
Canada (n = 2), China (n = 2), and Korea (n = 1). The remaining two studies were 
literature reviews, one a systematic review and the other a meta-analysis. (See Table 2.1.) 
The U.S.-based studies evaluated lung cancer stigma that represented three different 
regions: Northwest, Midwest, and Southeast. Study designs included analysis of 
covariates, correlational analysis, factor analysis, multiple linear regression, and repeated 
measures with interventions. Study participants were generally homogeneous in terms of 
ethnicity (Caucasian) and in the age range of 60–65 years. Participants included even 
numbers of males and females.  
The studies’ aims included understanding the impact on QOL related to stigma 
experienced by lung cancer survivors, specifically depression, guilt, shame, caregiver 
support, and patient-provider communication from the survivors’ perspectives. 
Interestingly, not all studies reported smoking status of the participants. Studies that did 
report smoking status reported a higher incidence of stigma among current and former 
smokers. Seven studies used an exploratory approach through a qualitative design. This 
allowed researchers to capture participants’ perspectives on stigma, societal attitudes 
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toward smoking and lung cancer, challenges related to stigma, and positive and negative 
results from the experience of stigma. In the articles included, investigators used survey 
instruments to measure lung cancer stigma, anger, anxiety, casual attribution, depression, 
QOL, self-blame, timing of medical help, diagnosis concealment, and/or provider-patient 
communication. One systematic review, published in 2012, assessed lung cancer stigma 
and its association with nihilism, health-related outcomes, and public health programs, 
and included studies with medical professionals as participants along with studies 
focused on support programs. Of the18 articles in the systematic review, this scoping 
review included three. In 2014, a meta-synthesis explored the experience of stigma 
among lung cancer survivors. Because of the meta-synthesis review’s broad aims, seven 
qualitative research studies were included. 
Stigma Instruments 
To evaluate lung cancer stigma among survivors, researchers measured stigma 
and related constructs with six instruments across the 30 studies (see Tables 2.1 and 2.2). 
The Cataldo Lung Cancer Stigma Scale (CLCSS) was used in nine studies. This 31-item 
instrument was adapted from Berger’s HIV Stigma Scale (Berger, Ferrans, & Lashley, 
2001; Calatdo et al., 2011). The four factors that emerged from this instrument (stigma 
and shame, social isolation, discrimination, and smoking) represent perception, blame 
and shame from others, the feeling of social strain and judgment, and the responsibility of 
acquiring the disease. Carter-Harris and Hall (2014) conducted a psychometric analysis 
and reduced the item number of the CLCSS to 21.  
LoConte, Else-Quest, Eickhoff, Hyde, and Schiller (2008) developed a six-item 
scale—derived from qualitative data obtained from previous lung cancer survivors’ focus 
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group discussions—called the Perceived-Cancer Related Stigma Scale. This instrument 
assessed self-blame, guilt, shame, and embarrassment among lung, breast, and prostate 
cancer survivors. Gonzalez and Jacobsen (2012) and Gonzalez and colleagues (2015) 
used the Social Impact Scale to measure the perception of stigma in relation to social 
rejection, financial insecurity, internalized shame, and social isolation. This scale 
assessed stigma in cancer populations and individuals diagnosed with HIV/AIDS. Shen 
and colleagues (2015) adapted the Head and Neck Cancer Shame and Stigma Scale (SSS) 
for lung cancer survivors. The SSS assessed perceived and internalize stigma, and the 
feelings of guilt and regret related to cigarette smoking.  
The Lung Cancer Stigma Inventory (LCSI) was developed by Hamann, Shen, 
Thomas, Lee, and Ostroff (2017). This 25-item instrument was derived from the 
conceptual model of lung cancer stigma developed earlier by Hamann and colleagues 
(2014). Three subscales emerged: perceived stigma, internalized stigma, and constrained 
disclosure. The LCSI was psychometrically evaluated and had adequate internal 
consistency and convergent validity with related constructs. Lebel, Castonguay et al. 
(2013) and Lebel, Feldstain et al. (2013) both used the Explanatory Model Interview 
Catalogue. This semi-structured interview was adapted into a 13-item questionnaire that 
explored stigma and illness disclosure and social rejection related to stigma. To date there 
are two instruments (the CLCSS and the LCSI) specifically prepared to evaluate lung 
cancer stigma that have been psychometrically tested and proven to have adequate 
reliability and validity.   
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Definitions of Lung Cancer Stigma 
Goffman’s (1963) work was the basis for a majority of studies (n = 13) in 
defining health-related stigma conceptually. His work laid the foundation for the initial 
conceptualization of stigma. He defined stigma as “an attribute that is deeply 
discrediting,” where the attribute in question is different from the normal status quo 
(Goffman, 1963, p. 3). A cancer diagnosis is often stigmatized because of a general 
misunderstanding or fear of cancer (Daher, 2012). Stigma can increase when a particular 
lifestyle or behavior is linked to the cancer (Cataldo et al., 2011; Lehto, 2014), as in the 
case of lung cancer and cigarette smoking (ALA, 2014; Dela Cruz, Tanoue, & Matthay, 
2011). Although Goffman provided the foundation, researchers since then have given 
different but meaningful definitions and descriptions of lung cancer stigma. This is true 
even though associated constructs are in alignment with all descriptions and definitions of 
stigma and its overall effects on lung cancer survivors’ QOL.  
Types of Stigma: Internal, External, and Perceived 
Chapple et al. (2004); Hamann et al. (2014); Lebel, Castonguay et al. (2013); and 
Shen, Hamann, Thomas, and Ostroff (2016) described stigma as having both internal 
(felt) and external (enacted) components. Felt stigma is internal to the survivor; examples 
include feelings of shame and guilt (Chapple et al., 2004; Lebel, Castonguay et al., 2013). 
Chapple et al. (2004); Hamann et al. (2014); and Tod, Craven, & Allmark’s (2008) 
qualitative studies reported participants feeling shame and guilt, which diminished their 
tendencies to seek health care, social interaction, and support. Internalized feelings may 
manifest as negative outcomes, such as social isolation and depression. Enacted stigma is 
external to the survivor, but is directed toward him or her from others, producing an 
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action (reaction or behavior) such as discrimination, blame, or social rejection (among 
other negative behaviors) (Chapple et al., 2004; Gonzalez & Jacobson, 2012). Stigma has 
been characterized as a perception that is felt by both the survivor and others (Brown-
Johnson et al., 2014; Cataldo, Jahan, & Pongquan, 2012; Cataldo et al., 2011; Criswell, 
Owen, Thornton, & Stanton, 2016; Gonzalez et al., 2015). Perceived stigma is the 
negative feeling survivors believe others have toward them and their cancer diagnosis 
(Brown & Cataldo, 2013; Cataldo et al., 2011; Chambers Baade et al., 2015; Lehto, 
2014).  
Our study concluded that lung cancer stigma is a threefold concept that involves 
survivors’ perceptions, survivors’ internalized feelings, and the feelings and actions of 
others toward survivors. There is often interplay among felt, enacted, and perceived 
stigma, amplifying or reinforcing the other stigmas. For example, lung cancer survivors 
are aware that others may believe that their cancer is self-inflicted via tobacco use, and 
that they may therefore be held responsible for their diagnosis. The anticipated blame, 
discrimination, and social rejection may lead to a sense of internal shame (Cataldo et al., 
2011; Lehto, 2014).  
Health Consequences of Stigma Among Lung Cancer Survivors 
 Of the studies that reported smoking status (n = 23), lung cancer survivors felt 
some sense of responsibility for their disease regardless of their smoking status (Brown & 
Cataldo, 2013; Cataldo et al., 2012; Cataldo et al., 2011; Else-Quest, LoConte, Schiller, 
& Hyde, 2009; Gonzalez et al., 2015; Shen et al., 2015). Current smokers experienced a 
higher level of guilt, shame, anxiety, and depression in comparison to former and never 
smokers (Cataldo et al., 2012; Else-Quest et al., 2009; LoConte et al., 2008). Former and 
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current smokers also experienced a higher level of depression and anxiety in comparison 
to individuals who were never smokers diagnosed with breast, colon, lung, stomach, 
cervix, head, or neck cancer (Lebel, Castonguay et al., 2013; Lebel, Feldstain et al., 2013; 
So, Chae, & Kim, 2017). Further validation was reported by Cataldo et al. (2011), 
Cataldo et al. (2012), and Gonzalez and Jacobsen (2012), where there was a significantly 
statistical strong positive association between stigma and depression with their study of 
lung cancer survivors. Brown-Johnson and colleagues (2014) found significant statistical 
associations among lung cancer stigma, depression, and anxiety. Chambers, Morris et al. 
(2015) introduced a cognitive behavioral intervention focused on lung cancer stigma in 
their pilot repeated measure study. They reported higher levels of depression, anxiety, 
and stigma pre-intervention, all three of which significantly decreased post-intervention. 
 Stigma affects psychological challenges and also complicates patient-provider 
communication (Brown & Cataldo, 2013; Brown-Johnson et al., 2014; Brown-Johnson et 
al., 2015; Cataldo et al., 2011; Chambers, Baade et al., 2015; Gonzalez & Jacobsen, 
2012; Hamann et al., 2014; Lehto, 2014; Shen et al., 2015; Yang, Liu, Yang, Ji, & Li, 
2014). Brown and Cataldo (2013) explored the experiences of women with lung cancer 
and found that lung cancer stigma negatively affected the patient-provider relationship. 
Other studies reported strong associations between the presence of stigma and adverse 
outcomes of depression, anxiety, self-esteem, QOL, and patient-provider communication 
(Brown-Johnson et al., 2014; Cataldo et al., 2012; Chambers, Baade et al., 2015; 
Gonzalez & Jacobsen, 2012; Gonzalez et al., 2015; Lehto, 2014; Yang et al., 2014). 
Researchers also found that perceived and internalized stigma altered patients’ 
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communication with their friends, family members, and health-care providers (Brown & 
Cataldo, 2013; Chapple et al., 2004; Hamann et al., 2014; Lehto, 2014).  
 Tod and colleagues (2008) and Scott, Crane, Lafontaine, Seale, and Currow 
(2015), in their qualitative studies, reported that blame, fear, and stigma all delayed 
patients’ seeking of medical assistance. Carter-Harris et al. (2014) reported from their 
linear regression that lung cancer stigma was predictive of increasing the time it takes for 
patients to seek care for lung cancer symptoms (X2 = 4.75, F = 12.44, p < 0.01), which 
prolonged lung cancer diagnosis. Studies reported that many lung cancer survivors are 
afraid of others’ reactions to their diagnosis (LoConte et al., 2008; Tod et al., 2008). 
Reactions of others may include discrimination by family, friends, and health-care 
providers, which led some to conceal their diagnosis (Cataldo et al., 2011; Hamann et al., 
2014; Shen et al., 2015). Gonzalez et al. (2015) found that internalized shame was a 
factor for those who did not disclose their diagnosis in comparison to those who did 
disclose it (n = 30/117, d = 0.63, t = -3.05, p < 0.01). Internalized shame and 
nondisclosure are two factors that validate the intertwining of the constructs related to 
lung cancer stigma. In addition, survivors reported experiencing feelings of isolation 
from friends and family as well as feelings of loneliness (Cataldo et al., 2011, Hamann et 
al., 2014). Gonzalez and Jacobsen (2012) evaluated depressive symptomology, including 
social support and its relationship with stigma. They reported an inverse relationship 
between social support and stigma experienced by (n=95) participants in their research 
study. Internalized shame and nondisclosure are intertwined constructs related to lung 
cancer stigma. Increases in depressive symptoms and anxiety have also been reported 
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(Cataldo et al., 2011; Cataldo et al., 2012; Gonzalez & Jacobsen, 2012; LoConte et al. 
2008).  
Discussion 
This scoping literature review presents the results of 30 peer-reviewed research 
studies that investigated stigma and lung cancer. The studies concentrated on the 
perspective of survivors and on the physical, psychological, and social influence of 
stigma. The findings present varied definitions of lung cancer stigma in terms of how this 
health-related stigma is experienced among survivors. Chapple and colleagues (2004) 
presented a foundational conceptualization that encompassed stigma of others and 
internal and perceived feelings of the lung cancer survivor. It is important to note that 
lung cancer stigma is a combination of awareness of social identity and survivors’ 
personal identity, which in turn leads to the awareness of potential negative actions of 
others. This combination may result in negative consequences for the survivors. Hamann 
and colleagues (2014) captured this in their conceptual model, which led to an instrument 
to measure the constructs of perceived/felt stigma and internalized/self-stigma. Hamann 
and colleagues’ model with the incorporation of adaptive and maladaptive consequences 
contributed to their conceptualization of lung cancer stigma.  
Lung cancer stigma stems from the link between cigarettes and the disease. 
LoConte and colleagues (2008) found that current or former smokers with lung cancer 
experienced a higher level of guilt, shame, and perceived stigma in comparison to women 
with breast cancer and men with prostate cancer. However, even never smokers 
experience lung cancer stigma. In fact, Cataldo et al. (2012) found a small difference in 
depression from perceived stigma and QOL among ever and never smokers. This 
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indicates that individuals with lung cancer experience altered QOL outcomes and 
depression regardless of their history with tobacco usage. This validates the need to 
consider that any lung cancer survivor may be affected by the negative influences of 
stigma.  
Self-blame and guilt may affect the decision and timeliness of seeking medical 
care (Carter-Harris et al., 2014). Although lung cancer survivors cannot control others’ 
perceptions or behaviors, perceived stigma nevertheless negatively affected their self-
evaluation, leading to an internalization of the stigma. Gonzalez and colleagues (2015) 
and Webb and McDonnell (2018) found that some lung cancer survivors concealed their 
diagnosis from family, friends, and acquaintances. Concealment of a chronic illness 
linked with stigma fosters a lack of support and social isolation. This may lead to further 
devaluation of the self and increased psychological challenges that may already exist 
among these survivors (Quinn, Weisz, & Lawner, 2017). Good health-care provider 
communication had a direct impact on the level of internalized and perceived stigma. 
Communication between providers and survivors is vital for the proper management of 
lung cancer, and when this communication is positive in nature, it helps identify and 
support the needs of lung cancer survivors. The quality and quantity of positive and 
beneficial communication between a health-care provider and a survivor is associated 
with decreased lung cancer stigma (Shen et al., 2016). When survivors sense 
preconceived blame, responsibility, or fatalism from others, altered communication may 
result. This may lead to their delay in seeking much-needed medical assistance and 
concealment of symptoms that need assessment and management. 
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Although this review summarizes and synthesizes substantial evidence regarding 
lung cancer stigma, knowledge gaps remain. Certain subpopulations of lung cancer 
survivors are underrepresented. African Americans, Pacific Islanders, and Native 
Americans have higher incident and mortality rates among all populations diagnosed with 
lung cancer (ACS, 2018). But only five studies had samples with adequate African 
American representation (Carter-Harris et al., 2014; Criswell et al., 2016; Gonzalez et al., 
2015; Hamann et al., 2014; Shen et al., 2016). No study had adequate representation of 
Pacific Islanders and Native Americans. Never smokers, who constitute 20% of 
individuals diagnosed with lung cancer (ACS, 2018), were not adequately represented in 
half of the studies. Further research is needed involving vulnerable populations, given the 
increased risk of negative outcomes for those living with lung cancer.  
This scoping literature review focused on stigma from the viewpoint of lung 
cancer survivors; however, exploration of the perceptions of family members, friends, 
caregivers, and health professionals is needed. A better understanding of how stigma 
impacts family members, friends and caregivers may assist with developing strategies to 
support and help survivors moderate stigma, which would improve survivors’ QOL. 
Another area that warrants investigation is the influence of anti-smoking campaigns, both 
on survivors’ internalization of lung cancer stigma and on the perceptions of family, 
friends, and health-care providers. 
 Lung cancer stigma affects a growing population of cancer survivors. Advancing 
knowledge of stigma can improve the care and QOL of this population. Developing 
effective education programs, awareness campaigns, and interventions can assist lung 
cancer survivors with the negative consequences of stigma. 
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Limitations of the Review 
 To our knowledge, this is the first scoping review to synthesize evidence from 
quantitative and qualitative studies relative to lung cancer survivors and stigma. For this 
reason, a scoping review was conducted rather than a systematic review or a meta-
synthesis. This review evaluated research on lung cancer stigma, determined the extent 
and type of research conducted to date, and identified gaps in this research area (Arksey 
& O’Malley, 2005). Despite our best efforts to uncover all relevant literature, we cannot 
disregard the possibility that some studies may not have been identified. Lastly, we did 
not limit this review to a specific methodology. The diversity of methods may have 
interfered with our ability to make accurate inferences related to lung cancer stigma.  
Implications for Oncology Nursing 
 Oncology nurses play a significant role in the lives of survivors with lung cancer 
and their family members and friends. To provide patient-centered care, it is essential for 
oncology nurses to understand the harmful impact of stigma. Developing strategies to 
promote meaningful communication with providers is essential for survivors and their 
family members, friends, and caregivers. In clinical settings, oncology nurses can 
advocate for improved communication with survivors, as well as an evaluation of stigma 
along with the survivors’ physical, psychological, social challenges, and QOL, to assist 
with planning individualized care. Advocating for the development and implementation 
of interventions that target outcomes related to decreasing physical and psychological 
burdens as well as social isolation is warranted. Although instruments have been 
developed for the evaluation of lung cancer stigma, more research is needed to develop 
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practical strategies to measure these constructs and develop interventions to minimize 
negative effects.  
Suggested Paths Forward 
Future investigations examining lung cancer stigma are imperative to improve 
patient-centered health care and QOL for lung cancer survivors. Research should focus 
on capturing specific experiences of stigma among subpopulations and amass the 
formative data that supports the development of tailored interventions for the most 
vulnerable subpopulations of lung cancer survivors. Such data will assist with decreasing 
the experience and consequences of stigma for all lung cancer survivors. 
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Table 2.1 Lung Cancer Stigma Study Review  
 
Study 
Design/ 
Aim(s) Method 
Participants 
(Setting) Results/Findings 
QUALITATIVE STUDIES 
Chapple, 
Ziebland, 
and 
McPherson 
(2004) 
Qualitative/ 
Explore 
perception of 
stigma among 
lung cancer 
patients  
 
 
One-to-one 
interviews 
focused on the 
perception of the 
cause of illness 
and how others 
reacted to the 
diagnosis 
▪ 45 participants 
 
▪ Gender not 
reported 
 
▪ 98% White 
  2% Indian 
 
▪ Smoking status 
not reported  
 
(United Kingdom) 
▪ Stigma was felt and 
enacted within this 
sample; these 
feelings may deter 
participants from 
seeking support and 
assistance (including 
financial) 
▪ Participants 
expressed anger that 
they were blamed for 
acquiring the disease 
Tod, 
Craven, 
and 
Allmark 
(2008) 
Qualitative/ 
Evaluate 
delayed 
reporting of 
lung cancer 
symptoms 
 
 
Individual 
interviews 
utilizing 
framework 
analysis for 
interpreting data 
▪ 20 participants  
 
▪ 60% male  
  40% female 
 
▪ 40% current 
  45% former 
  15% never  
 smokers 
 
▪ Race/ethnicity 
not reported 
 
(United Kingdom) 
▪ Participants stated 
that symptoms were 
varied and 
nonspecific 
▪ Generally lacked 
knowledge regarding 
symptoms, diagnosis, 
and treatment 
▪ Shame and guilt, 
fear, and stoicism 
were experienced 
among participants 
Brown and 
Cataldo 
(2013) 
Qualitative/  
Explore the 
experience of 
female long-
term lung 
cancer 
survivors in 
the context of 
LCS and 
examine how 
participants 
discursively 
adhere to or 
Exploratory 
one-to-one and 
group interviews 
focused on 
diagnosis, 
experience with 
health-care 
providers, 
experience of 
attitudes toward 
lung cancer, 
changes in 
social network, 
▪ 8 participants 
 
▪ 100% female 
 
▪ 62.5% ever,*  
 37.5% never  
smokers 
 
(USA/Northwest) 
▪ Experienced stigma 
in interactions with 
health providers 
▪ Expressed 
displeasure (negative 
connotation) in how 
they’re identified 
(smoker, lung cancer 
patient) 
▪ Conflict between 
rejecting and 
assuming stigma 
relative to diagnosis 
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Study 
Design/ 
Aim(s) Method 
Participants 
(Setting) Results/Findings 
reject 
stigmatizing 
beliefs 
 
 
and experience 
with stigma 
▪ Expressed that LCS 
interferes with an 
ideal patient-provider 
experience/ 
relationship 
Hamann et 
al. (2014) 
Qualitative/ 
Explore a 
conceptual 
model for 
LCS 
 
Individual 
interviews and 
focus group 
discussions to 
explore and 
describe the 
perception of 
lung cancer 
survivors’ 
▪ 42/65 individuals 
for interviews: 
 
▪ 48% male 
  52% female 
 
▪ 64% Caucasian 
  29% African  
  American 
  2% American 
  Indian/Alaska 
  Native 
  5% Asian or 
Pacific Islander  
 
▪ 24% current  
  50% former 
  26% never 
smoker 
  
▪ 23/65 individuals 
in focus group 
discussions: 
  
▪ 52% male 
  48% female 
  
▪ 70% Caucasian 
  22% African  
 American 
  9% Asian or 
Pacific Islander  
 
▪ 17% current 
  48% former 
  35% never 
smokers 
 
▪ Perceived stigma 
was pervasive 
throughout the entire 
sample, manifesting 
as devaluation and 
negative appraisal 
▪ Internalized stigma 
was affected by 
smoking history; 
long-term quitters 
and never smokers 
experienced less 
internalized stigma 
▪ Stigma-related 
consequences were 
seen as adaptive and 
maladaptive; 
recognized the need 
for intervention to 
promote adaptive 
consequences 
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▪ 17% current 
  48% former 
  35% never 
smokers 
 
(USA/Southwest) 
Lehto 
(2014) 
Qualitative/ 
Aim 1: 
Describe the 
lung cancer 
experience in 
relation to 
perceived 
stigma-
tization, 
smoking 
behaviors, 
and illness 
causes; 
Aim 2: 
Discuss these 
findings 
relative to the 
role of the 
nurse as a 
patient 
advocate 
Focus group 
interviews 
focused on 
discussing 
patient 
perceptions of 
lung cancer 
challenges and 
adaptation 
issues 
 
▪ 11 participants 
 
▪ 45% male 
  55% female 
 
▪ 100% Caucasian  
 
▪ Smoking status 
not reported 
 
(USA/Midwest) 
Emergent themes 
included societal 
attitudes; institutional 
practices and 
experiences; negative 
thoughts and 
emotions such as 
guilt, self-blame and 
self-deprecation, 
regret, and anger; 
actual stigmatization 
experiences; smoking 
cessation; personal 
choices versus 
addiction; and causal 
attributions 
Scott, 
Crane, 
Lafontaine, 
Seale, and 
Currow 
(2015) 
Qualitative/ 
Evaluate 
stigma as a 
barrier to 
seeking 
medical 
attention 
from the 
perspective of 
the lung 
cancer 
survivor and 
health 
professionals  
 
Semi-structured 
interviews  
▪ 20 participants  
 
▪ 60% male  
  40% female 
 
▪ Ethnicity/race 
not reported 
 
▪ 65% former 
  35% never 
smokers  
 
 (Australia) 
▪ Lung cancer 
survivors reported 
stigmatization and 
blame for acquiring 
the disease secondary 
to tobacco 
▪ Anti-smoking ads 
perpetuate the stigma 
▪ Health-care 
professionals 
indicated placing a 
sense of responsibil-
ity on the survivors 
partly due to the 
“choice” of smoking 
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Jeong, 
Jeong, and 
So (2016) 
Meta-
synthesis/ 
Explore and 
synthesize the 
experience of 
stigma among 
lung cancer 
survivors in 
qualitative 
studies 
Review of 
qualitative 
studies utilizing 
the process 
according to 
Sandelowski 
and Barroso 
(2007) 
7 qualitative 
studies  
 
(3 USA, 3 United 
Kingdom, 1 
Australia) 
Themes synthesized 
included: 
Experiencing some 
distance from the 
surrounding world; 
experiencing self-
made distance 
between the disease 
and oneself; the 
disease experience 
causes social 
isolation and 
loneliness; and there 
is a lack of 
supportive care for 
myself 
Liu et al. 
(2016) 
 
Qualitative/D
escribe 
experiences 
of lung 
cancer 
survivors in 
China relative 
to stigma and 
coping 
strategies  
Qualitative 
(exploratory) 
study utilizing 
semi-structured 
individual 
interviews to 
obtain data and 
analyze 
▪ 17 participants 
 
▪ 59% male  
  41% female 
 
▪ Ethnicity/race 
not reported  
 
▪ Smoking status 
not 
 reported 
 
(China) 
3 themes identified: 
(1) sources of 
stigma—smoking, 
decreased 
functioning, damage 
to self-image; (2) 
experience of stigma, 
perceived 
discrimination, social 
isolation; (3) coping 
with stigma—
concealment, giving 
explanation about 
disease, cooperation 
with medical 
professionals, 
disclosing 
dissatisfaction with 
discrimination 
Rowland et 
al. (2016) 
 
Qualitative/ 
Explore QOL 
and support 
experiences 
among 
individuals 
with 
advanced 
Semi-structured 
interviews were 
analyzed using 
interpretative 
phenomeno-
logical analysis 
▪ 9 participants 
 
▪ 67% male 
  33% female 
 
 
▪ 67% former  
  33% current 
▪ Themes identified: 
effect of illness on 
QOL—depended on 
how physical tasks 
are achieved; family 
support—good but 
experienced 
changing roles; 
40 
Study 
Design/ 
Aim(s) Method 
Participants 
(Setting) Results/Findings 
lung cancer 
 
 
smokers 
 
▪ Race/ethnicity 
not reported 
 
(United Kingdom) 
coping strategies 
were varied; medical 
support 
communication was 
challenged, and 
smoking status 
predicted this at 
times; smoking—
social stigma, 
acknowledgement of 
etiology related to 
diagnosis 
QUANTITATIVE STUDIES 
LoConte, 
Else-Quest, 
Eickhoff, 
Hyde, and 
Schiller 
(2008)  
Quantitative/ 
Evaluate guilt 
and shame in 
non-small-
cell lung 
cancer 
patients in 
comparison 
to breast and 
prostate 
cancer 
 
 
Repeated 
measure surveys 
at three time 
points using 
means to 
evaluate 
between 
subjects; 
multiple 
analysis of 
covariance. 
stigma measured 
with Perceived 
Cancer Related 
Stigma (non-
validated 
instrument) and 
the State Shame 
and Guilt Scale 
(SSGS; 
measures guilt 
and shame) 
▪ 96 participants 
 
▪ 51% male 
  49% female 
 
▪ 94% White 
  2% Black 
  1% Native 
American  
  1% Hispanic  
 
▪ 11.5 % current 
  80% former 
  8% never 
smokers 
 
(USA/Midwest) 
▪ Those with lung 
cancer had a higher 
level of perceived 
stigma than 
individuals with 
breast and prostate 
cancer 
▪ Smokers overall 
had a higher level of 
shame and guilt, 
anxiety, and 
depression regardless 
of cancer’s cause 
▪ Guilt and shame 
did not increase or 
decrease over the 
three time points for 
all cancers 
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Else-Quest, 
LoConte, 
Schiller, 
and Hyde 
(2009)  
Quantitative/ 
Aim 1: 
Assess cancer 
patients’ 
experience of 
stigma and 
self-blame 
after 
diagnosis of 
breast, lung, 
and prostate 
cancer; 
Aim 2: 
Explore 
stigma, 
shame, and 
self-blame 
(internal 
attribution) 
relative to 
psychological 
adjustment 
(anxiety, 
anger, 
depression, 
self-esteem, 
and causal 
attribution for 
cancer) 
among cancer 
survivors 
Bivariate and 
multivariate 
correlation 
examining 
differences 
between the 
cancer groups; 
hierarchical 
regression 
examining 
mediation 
between self-
blame and 
perceived 
stigma; 
perceived 
stigma measured 
with Perceived 
Cancer Related 
Stigma (non-
validated 
instrument) 
developed by 
authors; causal 
attribution 
evaluated using 
thematic content 
analysis 
▪ 96/172 
participants with 
lung cancer  
 
▪ 51% male    
 49% female 
 
▪ 94% White 
  3% African 
American 
  2 % Native 
American  
 < 1% Hispanic 
 
 ▪ 92% current or 
former smokers 
 
(USA/Midwest) 
 
▪ Strong correlation 
between self-blame, 
self-esteem, and 
perceived stigma for 
all participants 
▪ Participants (all 
cancers) who 
reported internal 
attribution had higher 
self-blame, lower 
self-esteem, higher 
anxiety, and higher 
depression  
▪ Lung cancer 
participants reported 
more internal 
attribution/behavioral 
cause of disease 
Cataldo, 
Slaughter, 
Jahan, 
Pongquan, 
and Hwang 
(2011) 
Psychometric 
analysis/  
Develop and 
evaluate an 
instrument to 
measure 
perceived 
stigma of 
individuals 
with lung 
cancer 
 
Exploratory 
online survey 
for factor 
analysis for 
construct 
validity; 
correlations to 
establish 
criterion-related 
validity and 
measure internal 
consistency 
▪ 186 participants  
 
▪ 30% male 
  70% female 
 
▪ 86% White  
  8% Asian 
  2% Hispanic  
  3.2% Other 
 
▪ 79% current 
smokers  
▪ The authors 
validated the scale 
that was developed to 
measure components 
of stigma  
▪ 4 subscales 
identified: 
shame/stigma, social 
isolation, 
discrimination, 
smoking 
▪ Associations 
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 reliability of 
CLCSS 
  21% non-smokers 
 
 (USA/38 states) 
between perception 
of LCS and 
depression, QOL, 
social support and 
conflict, and self-
esteem 
Cataldo, 
Jahan, and 
Pongquan 
(2012)  
 
Quantitative/ 
Aim 1: 
Examine the 
relationship 
of LCS, 
depression, 
and QOL; 
Aim 2: 
Explore 
impact of 
LCS on QOL, 
adjusting for 
age, gender, 
smoking 
status, and 
depression 
 
 
Online 
questionnaire 
examining the 
association 
between self-
reported LCS 
and depression 
and QOL, with 
comparison 
between lung 
cancer 
participants who 
were smokers 
and non-
smokers using 
CLCSS 
▪ 190 participants 
 
▪ 56% male  
  43% female  
 
▪ 85% Caucasian 
  1.5% African 
  American  
  8.4% Asian or 
Pacific Islander 
  1.5% Hispanic 
  0.5% American 
Indian 
  1% More than 
one ethnicity 
 
▪ 80% ever* 
  20.5% never 
smokers 
 
(USA) 
▪ Positive 
relationship between 
LCS and depression 
▪ Inverse relationship 
between LCS and 
QOL 
▪ LCS significantly 
contributed to the 
explanation of QOL 
▪ Small difference 
between ever 
smokers* and never 
smokers 
Chambers 
et al. (2012)  
 
Systematic 
review/ 
Assess the 
influence of 
stigma and 
nihilism on 
lung cancer 
care QOL and 
psychosocial 
well-being 
The search was 
guided by 
stigma and 
medical 
treatment 
outcomes, 
psychosocial 
outcomes, and 
public health 
impact; assessed 
LCS or nihilism 
and included an 
outcome of 
interest relative 
to survival, 
delayed 
▪ 15 articles 
reviewed and 
discussed:   
  7 qualitative 
  8 quantitative 
 
▪ LCS has an adverse 
effect on 
psychosocial well-
being and overall 
QOL  
▪ Felt, perceived, and 
enacted stigma are 
experienced by many 
with lung cancer 
▪ Did not find a clear 
indication of nihilism 
in association with 
stigma 
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presentation, 
treatment 
adherence or 
refusal, patterns 
of care, 
psychological 
distress, 
psychological 
help seeking or 
QOL 
Gonzalez 
and 
Jacobsen 
(2012) 
Quantitative/ 
Examine 
possible 
association 
between 
perceived 
stigma related 
to a lung 
cancer 
diagnosis and 
depressive 
symptom-
atology 
Correlational 
analysis from a 
questionnaire 
and self-
reported 
measures 
assessing 
perceived 
stigma, 
depressive 
symptom- 
atology, and a 
chart review to 
supplement this 
information; 
SIS-Stigma was 
used 
▪ 95 participants  
 
▪ 41% male 
 59% female 
  
▪ 92.6% White- 
  Caucasian 
  7.4% Non-White 
 
▪ 15.7% current  
  71.5% former 
  13.3% never  
 smokers 
  
(USA/Southeast) 
▪ Degree of 
perceived stigma is 
significantly related 
to depressive 
symptomatology 
▪ Poorer social 
support, more 
avoidant coping, and 
more dysfunctional 
attitudes were 
significantly related 
to greater depressive 
symptomatology 
Lebel, 
Caston-
guay et al. 
(2013)  
Quantitative/ 
Examine 
cancer-related 
stigma, 
determinants, 
and 
psychosocial 
impacts in 
lung and head 
and neck 
cancer 
survivors 
 
 
Self-reported 
questionnaires 
for correlations 
between stigma, 
behavioral self-
blame, 
disfigurement, 
illness 
intrusiveness, 
benefit finding, 
distress, and 
subjective well-
being and 
sociodemo-
graphic and 
medical 
▪ 107/206 
participants with 
lung cancer 
 
▪ 40% male 
  60% female 
 
▪ 12% current 
  79% former 
  8% never 
smokers 
 
▪ Ethnicity/race 
not reported 
 
(Toronto, Canada) 
▪ Lung cancer 
survivors had higher 
self-blame and higher 
stigma than head and 
neck cancer survivors 
▪Self-blame did not 
predict stigma 
▪ Stigma correlated 
significantly and 
positively with 
distress and 
negatively with well-
being 
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variables; 
hierarchical 
multiple 
regression to 
predict the 
impact of stigma 
on distresses and 
well-being; 
stigma by cancer 
site, age, self-
blame, and 
disfigurement; 
measured stigma 
with 13-item 
sub-scale from 
the Explanatory 
Model Interview 
Catalogue 
 
Lebel, 
Feldstain et 
al. (2013) 
Quantitative/ 
Examine 
cancer-related 
stigma, 
determinants, 
and 
psychosocial 
impacts in 
lung and head 
and neck 
cancer 
survivors and 
its 
relationship 
to positive 
health 
changes 
 
 
Correlational 
analyses were 
conducted 
examining the 
associations 
between positive 
health changes  
Sociodemo-
graphic and 
medical 
variables. 
Hierarchical 
multiple 
regression to 
examine the 
predicted power 
of stigma, self- 
blame, age, 
radiation 
treatment, and 
smoking status 
in relationship to 
positive health 
changes. 
Utilized 13-item 
▪ 107/206 
participants, lung 
cancer survivors 
 
▪ 40% male 
  60% female 
 
▪ 12% current 
  79% former 
  8% never 
smokers 
 
▪ Ethnicity/race 
not reported 
 
(Toronto, Canada) 
 
▪ In comparison to 
other cancer 
survivors, lung 
cancer survivors 
experienced higher 
levels of stigma and 
self-blame, and lower 
positive health 
changes 
 
▪ Behavioral self-
blame significantly 
predicted adoption of 
positive health 
changes whereas 
stigma did not 
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sub-scale from 
the Explanatory 
Model Interview 
Catalogue to 
measure 
perceived 
stigma. 
Carter-
Harris and 
Hall (2014)  
Psychometric 
analysis/ 
Aim 1: 
Investigate 
the 
dimension-
ality of the 
original 
CLCSS in a 
sample of 
lung cancer 
patients; 
Aim 2: 
Evaluate 
internal 
consistency 
reliability of 
the original 
CLCSS; 
Aim 3: 
Shorten the 
CLCSS using 
exploratory 
factor 
analysis and 
reliability 
indicators 
Self-reported, 
written surveys 
followed by 
semi-structured 
interviews; 
principle 
component 
analysis used to 
assess 
dimensionality 
followed by 
exploratory 
factor analysis; 
reliability tested 
using Cronbach 
alpha 
 
▪ 94 participants 
 
▪ 38% male 
  62% female  
 
▪ 83% White 
  17% African 
 American 
 
▪ 68% ever* 
  32% never 
smokers 
 
 (USA/Southern 
Midwest) 
▪ 3 factors identified: 
shame and blame; 
social isolation; 
discrimination 
▪ Scale decreased to 
21 from 31 items 
with internal 
consistency of .93 
(compared to .95 for 
the 31-item scale) 
Carter-
Harris, 
Hermann, 
Schreiber, 
Weaver, 
and Rawl 
(2014)  
 
Quantitative/ 
Examine 
relationships 
among 
demographic 
variables, 
health-care 
system 
distrust, lung 
Cross-sectional, 
correlational 
study using self-
reported surveys 
followed by 
semi-structured 
interview; 
CLCSS used to 
measure stigma 
▪ 93 participants 
 
▪ 38% male 
  62% female 
 
▪ 83% Caucasian 
  17% African 
 American 
 
▪ Associations 
present among time 
from symptom onset 
to medical help, 
health-care system 
distrust, LCS, 
smoking status, 
income, ethnicity, 
and social 
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cancer, 
stigma, 
smoking 
status, and 
timing of 
medical care 
 
▪ 32% current 
  35% former 
  32% never 
smokers 
 
(USA/Southern 
Midwest) 
desirability 
▪ LCS was a 
significant predictor 
of increased time 
from symptom onset 
to seeking medical 
help 
Brown-
Johnson, 
Brodsky, 
and 
Cataldo 
(2014)  
 
 
Quantitative/ 
Investigate 
LCS anxiety, 
depression, 
and QOL 
among ever* 
and never 
smokers 
 
 
Descriptive 
cross-sectional 
study; 
correlational 
analyses and 
hierarchical 
multiple 
regression were 
performed using 
multiple surveys 
for anxiety, 
depression, and 
QOL; CLCSS 
▪ 149 participants 
 
▪ 25% male 
 75% female 
 
▪ 93% Caucasian 
  7% Non-
Caucasian 
 
▪ 80% ever* 
  20% never 
smokers 
 
 (USA)  
▪ Significant negative 
relationships between 
QOL, and anxiety 
and depression, and a 
significant negative 
relationship between 
LCS and total QOL 
▪ Significant 
associations with 
LCS and three of the 
four QOL subscales 
(physical, 
psychological, and 
social well-being) 
▪ Smoking status did 
not affect LCS, 
depression, or QOL 
Yang, Liu, 
Yang, Ji, 
and Li 
(2014)  
Psychometric 
analysis/ 
Test 
reliability and 
validity of the 
Chinese 
version of 
CLCSS for 
lung cancer 
survivors 
Exploratory 
factor analysis; 
correlational 
design for 
construct 
validity; 
Cochran’s alpha 
for reliability 
▪ 117 participants 
  
▪ 74% male 
  26% female 
 
▪ Ethnicity/race 
not reported 
 
▪ Smoking status 
not reported 
 
(China) 
▪ Negative 
association between 
all stigma factors and 
self-esteem  
▪ Positive association 
between all stigma 
factors and 
depression 
Chambers, 
Baade et al. 
(2015) 
 
Quantitative/ 
Describe the 
impact of 
stigma on 
lung cancer 
patients’ 
Cross-sectional 
survey 
examining 
psychological 
distress and 
QOL after 
▪ 151 participants 
 
▪ 52% male 
  48% female  
 
▪ 72% Australia-
▪ An increase of 
stigma, shame, and 
discrimination was 
associated with 
increased anxiety 
▪ A higher level of 
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psychological 
distress and 
QOL 
 
 
diagnosis of 
lung cancer; 
health-related 
stigma, social 
constraints, and 
illness 
appraisals were 
assessed as 
predictors of 
adjustment 
outcomes; 
surveys 
measured 
psychological 
distress 
(depression and 
anxiety), QOL, 
social 
constraints, and 
stigma (using 
CLCSS); 
hierarchical 
regression used 
born 
 28% Other  
 
▪ Specific 
race/ethnicity not 
reported 
 
▪ 83% ever* 
 17% never 
smokers 
 
(Australia) 
shame related to 
stigma was 
associated with 
increased depression 
▪ An association 
between stigma, and 
shame and distress, 
was established; also, 
stigma and shame 
had a significant 
association with 
QOL 
Chambers, 
Morris et 
al. (2015) 
 
Mixed 
methods/ 
Test the 
acceptability 
of a focused 
cognitive 
behavioral 
intervention 
targeting 
stigma for a 
group of 
patients with 
lung cancer 
 
 
Intervention was 
a 6-week 
telephone self-
help 
intervention—
stigma, QOL, 
depression, and 
cancer-related 
distresses were 
measured prior 
to the 
intervention for 
baseline and in 
months after 
study began; 
interview with 
participants 
completed at 3 
months to assess 
acceptability of 
▪ 25 participants 
 
▪ 12% male 
  88% female 
 
▪ Ethnicity/race 
not reported 
 
▪ 28% current  
 52% former 
 20% never 
smokers 
 
 (Australia) 
▪ Overall stigma 
score decreased at 
the second time 
point; the subscale of 
discrimination did 
not have a substantial 
change 
▪ Psychological 
outcomes also 
improved 
▪ Stigma was a theme 
identified from the 
interviews post-
intervention 
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the intervention; 
stigma measured 
with CLCSS 
Gonzalez et 
al. (2015)  
Quantitative/ 
Examine lung 
cancer 
diagnosis 
concealment 
and its 
association 
with LCS, 
social anxiety 
and social 
avoidance, 
coping 
strategies, 
support 
systems, 
anxiety and 
depression, 
and self-
esteem 
Correlational 
design to 
evaluate 
demographics 
and clinical 
variables with 
concealment of 
cancer 
diagnosis; 
hierarchical 
regression 
analysis to 
predict 
concealment; 
SIS-Stigma used 
▪ 117 participants 
 
▪ 50% male 
  50% female 
 
▪ 82% Caucasian 
 18% Non- 
Caucasian  
 
▪ 78% ever* 
  22% never 
smokers 
  
(USA/Southeast) 
 
▪ 26% of participants 
concealed their 
diagnosis  
▪ Strong association 
between concealment 
and internalized 
shame 
▪ Anxiety, 
depression, cancer-
specific distress, 
social avoidance, and 
self-esteem not 
associated with 
diagnosis 
concealment 
Shen et al. 
(2015)  
Quantitative/ 
Aim 1: 
Examine 
post-
traumatic 
growth 
among lung 
cancer 
survivors as a 
potential 
buffer against 
the 
relationship 
between 
stigma and 
psychological 
distress; 
Aim 2: 
Examine how 
these 
relationships 
Hierarchical 
linear regression 
utilizing 
multiple surveys 
on 
psychological 
distress stigma, 
post-traumatic 
growth, and 
demographics; 
Shame and 
Stigma scale 
 
▪ 141 participants 
 
▪ 38% male 
  62% female 
 
▪ 95% Caucasian 
  3% African 
  American 
 
▪ 70% former pre 
diagnosis smoking 
quitters 
  30% former post-
diagnosis quitters 
  20% never 
smokers 
 
 (USA/Northeast) 
▪ LCS significantly 
associated with 
psychological 
distress 
▪ High levels of post-
traumatic growth 
among pre-diagnosis 
smoking quitters; 
however, higher 
stigma levels were 
associated with 
higher levels of 
psychological 
distress 
▪ Among post-
diagnosis quitters, 
stigma was 
associated with 
higher levels of 
psychological 
distress at low levels 
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differed by 
the timing of 
quitting 
smoking 
of post-traumatic 
growth 
Criswell, 
Owen, 
Thornton, 
and 
Stanton 
(2016)  
Psychometric 
analysis/ 
Evaluate 
Cancer 
Responsibil-
ity and Regret 
Scale 
 
  
Factor analysis 
of the scale, 
which measures 
the constructs of 
medical stigma, 
personal 
responsibility, 
and regret; 
correlational 
design to 
compare 
measures among 
never smokers, 
former smokers, 
and current 
smokers 
▪ 213 participants 
 
▪ 44% male 
  56% female  
 
▪ 80% Caucasian 
 18% Other 
  
▪ 18% current 
  66% former 
  16% never 
smokers 
 
(USA/Western) 
▪ Current and former 
smokers had higher 
personal 
responsibility and 
regret than never 
smokers 
▪ All smoking 
statuses reported 
medical stigma with 
very little difference 
between 
current/former 
smokers and never 
smokers; greater 
medical stigma was 
associated with 
worsening 
psychological 
functioning  
Shen, 
Hamann, 
Thomas, 
and Ostroff 
(2016) 
 
 
Quantitative/ 
Evaluate 
patient-
provider 
communi-
cation and its 
association 
with LCS 
 
 
 
Surveys 
completed by 
participants on 
tablet computer 
through a secure 
electronic (web-
based) portal, 
using their own 
computer, or a 
paper-based 
version of the 
survey; stigma 
measured with 
CLCSS; 
bivariate 
correlations and 
multivariate 
regression 
assessed 
association and 
▪ 231 participants 
 
▪ 36% male  
  64% female 
 
▪ 79% Caucasian 
  14% African 
 American 
▪ 9% current  
 65% former  
 26% never 
smokers 
 
(USA/Multisite 
recruitment) 
▪ Good patient-
provider 
communication is 
associated with lower 
stigma 
▪ Age and marital 
status were 
significantly 
associated with 
stigma 
▪ No association 
between smoking 
status and LCS 
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significance of 
stigma, patient-
provider 
communication, 
and smoking 
status 
Hamann, 
Shen, 
Thomas, 
Lee, and 
Ostroff 
(2017)  
Psychometric 
analysis/ 
Evaluate 
newly 
developed 
LCSI 
 
 
 
 
Exploratory 
factor analysis 
on phase III 
participants of 
this study; 25-
item survey 
developed and 
validated 
▪ 231 participants 
 
▪ 36% male 
  64% female 
 
▪ 79% Caucasian 
  14% African 
 American 
 
▪ 8% current  
  65% former 
  26% never 
smokers 
 
(USA/South) 
▪ Internal consistency 
0.89; convergent 
validity (CLCSS) r = 
.58 
▪ Three factors 
identified: internal 
stigma, perceived 
stigma, constrained 
disclosure 
So, Chae, 
and Kim 
(2017)  
Psychometric 
analysis/ 
Evaluate 
reliability and 
construct 
validity of the 
Korean 
Cancer 
Stigma Scale 
(adapted from 
CLCSS) 
Exploratory 
factor analysis 
and construct 
validity 
performed  
▪ 50/247 
participants with 
lung cancer  
 
▪ 40% of 247 male 
  60% of 247 
female  
 
▪ Ethnicity/race 
not reported  
 
▪ Smoking status 
not reported 
 
 (South Korea) 
Factors identified: 
social isolation, 
distancing/ 
avoidance, 
discrimination, guilt, 
attribution, lack of 
medical support 
Weiss et al. 
(2017) 
 
 
 
 
Quantitative/ 
Understand 
lung cancer 
survivors’ 
experiences 
and attitudes 
Phone and 
online surveys 
administered to 
evaluate 
perceived 
stigma, self-
▪ 174 participants 
 
▪ 52% male  
  48% female 
 
▪ 91% Caucasian 
▪ Stage III 
participants (43% of 
all in study) indicated 
a high level of 
perceived stigma 
from society as a 
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Study 
Design/ 
Aim(s) Method 
Participants 
(Setting) Results/Findings 
 
 
toward 
stigma, self-
blame, and 
medical care 
satisfaction  
 
 
 
blame, and 
satisfaction of 
care; 
correlational 
design used to 
assess 
associations 
with these 
factors and 
demographic 
characteristics; 
non-validated, 
63-item survey 
developed by 
Health 
Communication 
Company 
  9% Other  
 
▪ 19% current  
  68% former 
  13% never 
smokers 
 
(USA) 
 
whole 
▪ Low correlation 
between stigma and 
self-blame; current 
and former smokers 
were more likely to 
report self-blame, 
and smoking history 
was strongly 
correlation with 
stigma 
Note. Studies are presented in chronological order of publication (and then in alphabetical order for 
publications from the same year). LCS = lung cancer stigma; QOL = quality of life; SIS = Social Impact 
Scale; CLCSS = Cataldo Lung Cancer Stigma Scale; PSS = Perceived Stigma Scale; LCSI = Lung Cancer 
Stigma Inventory. 
* An ever smoker is one who either currently smokes or previously smoked in the past. 
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Table 2.2 Scoping Literature Review Instruments Assessing Lung Cancer Stigma 
 
Instrument 
Authors 
(Year) Dimensionality 
Scoring 
Procedure Method(s) 
Reliability 
Coefficient 
Alpha Validity 
Cataldo Lung 
Cancer Stigma 
Scale 
Brown-
Johnson, 
Brodsky, and 
Cataldo 
(2014); 
Carter-Harris 
and Hall 
(2014); 
Carter-
Harris, 
Hermann, 
Schreiber, 
Weaver, and 
Rawl (2014); 
Cataldo, 
Jahan, and 
Pongquan 
(2012); 
Cataldo, 
Slaughter, 
Jahan, 
Pongquan, 
and Hwang 
(2011); 
Chambers, 
Baade et al. 
(2015); 
Chambers, 
Morris et al. 
(2015); Shen, 
Hamann, 
Thomas, and 
Ostroff 
(2016); So, 
Chae, and 
Kim (2017); 
Yang, Liu, 
Yang, Ji, and 
Li (2014) 
Exploratory 
factor analysis 
yield, 4 
domains:  
stigma and 
shame, social 
isolation, 
discrimination, 
smoking 
 
 
 
 
Balanced 
31-item 
Likert 4-
point 
scale: 1 = 
Strongly 
Agree; 4 = 
Strongly 
Disagree 
 
 
Psychometric 
testing: internal 
consistency, 
construct 
validity, and 
criterion 
validity; 
additional 
analysis 
included 
correlations, 
multiple 
regression 
 
Total Scale: 
0.96; for 
each 
domain—
stigma and 
shame: 0.97; 
social 
isolation: 
0.97; 
discriminati
on: 0.92; 
smoking: 
0.74  
Criterion-
related 
validity 
supported 
by 
correlation; 
predicted 
direction of 
association 
with similar 
constructs: 
depression, 
QOL, social 
support, 
social 
conflict, 
self-esteem 
Cancer 
Responsibility 
and Regret 
Scale 
Criswell, 
Owen, 
Thornton, 
and Stanton 
(2016) 
Exploratory 
factor analysis 
yield, 3 
domains: 
personal 
responsibility, 
regret, medical 
stigma  
Balanced 
23-item 7-
point 
Likert 
scale 
Factor analysis, 
correlational 
analysis, and 
multiple linear 
regression 
 
Personal 
responsi-
bility: 0.84; 
regret: 0.64; 
medical 
sigma: 0.71 
Construct 
validity 
done with 
Pearson 
correlation 
with 
measure 
from similar 
constructs 
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Instrument 
Authors 
(Year) Dimensionality 
Scoring 
Procedure Method(s) 
Reliability 
Coefficient 
Alpha Validity 
Explanatory 
Model 
Interview 
Catalogue 
Lebel, 
Castonguay 
et al. (2013); 
Lebel, 
Feldstain et 
al. (2013) 
13-item 
subscale 
adapted from 
interview to 
questionnaire 
Balanced  
13-item 
Likert 4-
point scale 
based on 
agreement 
of 
statement 
Correlational 
and hierarchical 
multiple 
regression 
 0.82 Not 
assessed 
Lung Cancer 
Stigma 
Inventory 
Hamann, 
Shen, 
Thomas, Lee, 
and Ostroff 
(2017) 
Exploratory 
factor analysis 
yield, 3 factors: 
internalized 
stigma, 
perceived 
stigma, 
constrained 
disclosure 
Balanced 
25-item 
Likert 5-
point 
scale: 1 = 
Not at All; 
5 = 
Extremely 
Preliminary 
psychometric 
testing; internal 
consistency; 
test-retest 
correlation and 
convergent 
validity 
0.89; test-
retest 
correlation r 
= 0.91 
Convergent 
validity with 
CLCSS was 
r = .58 
Perceived 
Stigma Scale 
 
LoConte, 
Else-Quest, 
Eickhoff, 
Hyde, and 
Schiller 
(2008); Else-
Quest, 
LoConte, 
Schiller, and 
Hyde (2009) 
Not assessed Balanced 
6-item 
Likert 5-
point 
scale: 1 = 
Strongly 
Agree; 5 = 
Strongly 
Disagree 
Repeated 
measures of 
stigma, guilt, 
and shame 
0.75 Not 
assessed 
Shame and 
Stigma Scale  
LoConte et 
al. (2008); 
Shen et al. 
(2015) 
Exploratory 
factor analysis 
yield for 
original scale, 
4 domains: 
shame with 
appearance, 
sense of 
stigma, regret 
and speech, 
social concerns 
Balanced 
20-item 
Likert 5-
point 
scale: 1 = 
Never; 5 = 
All the 
Time 
Internal 
consistency for 
adaption for lung 
cancer; bivariate 
correlations with 
stigma and other 
related variables 
and hierarchical 
linear regression 
between stigma, 
anxiety, and 
depression, 
controlling for 
demographics  
Total (2 
domains): 
0.81 
(internal 
stigma 
domain: 
0.77; 
perceived 
stigma 
domain: 
0.79) 
 
Construct 
validity with 
preliminary 
psycho-
metric 
testing with 
Pearson 
correlation 
with similar 
constructs 
Social Impact 
Scale 
Gonzalez and 
Jacobsen 
(2012); 
Gonzalez et 
al. (2015)  
 
 
Factor analysis 
yield, 4 
domains: social 
rejection, 
financial 
insecurity, 
internalized 
shame, social 
isolation 
Balanced 
24-item 
Likert 4-
point scale 
Correlational 
design and 
hierarchical 
linear regression 
 0.95 Construct 
validity 
tested 
previously 
and 
established 
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Figure 2.1 Sample Selection Process  
  
163 ARTICLES RETRIEVED IN INITIAL SEARCH 
Web 
of Science 
n = 59 
CINAHL 
n = 43 
PubMed  
n = 35 
PsycINFO  
n = 26 
114 articles deleted from search due to duplication 
between databases 
19 articles deleted due to: 
Aims not specific to stigma and lung cancer  
Commentary article or meeting abstract 
30 articles included in this scoping review 
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CHAPTER 3: 
EVALUATION OF LUNG CANCER STIGMA WITH THE CATALDO LUNG 
CANCER STIGMA SCALE AMONG AFRICAN AMERICAN SURVIVORS OF 
LUNG CANCER IN SOUTH CAROLINA2 
                                                 
2 Webb, L. A., McDonnell, K. K., Adams, S. A., Davis, R. E., Donevant, S., and Felder, T. M. To be 
submitted to the Journal of Psychosocial Oncology. 
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Abstract 
Purpose: 
To evaluate the reliability and validity of the Cataldo Lung Cancer Stigma Scale 
(CLCSS) and to explore its interpretation among African Americans in South Carolina.   
Research Approach: 
Multiple methods, utilizing correlational and thematic analysis. 
Sample: 
A purposive sample of 26 African Americans, who completed self-report surveys. 
Ten participated in one-to-one interviews.  
Findings: 
Participants reported a moderate level of lung cancer stigma, depressive 
symptoms, and quality of life (QOL). Depressive symptoms were positively associated to 
lung cancer stigma, and QOL was negatively associated to lung cancer stigma. Thematic 
analysis revealed social isolation, regrets, and discrimination.  
Conclusions: 
The CLCSS was a reliable instrument for evaluating LCS among this sample of 
African Americans. However, further evaluation of the CLCSS is needed to assess 
cultural considerations among African Americans. Depressive symptoms and lung cancer 
stigma share a link and may contribute to better understanding of QOL among African 
American lung cancer survivors.  
Implications for Psychosocial Providers: 
Lung cancer stigma manifests itself differently among individuals, races, and 
ethnicities. It is important for health professionals to acknowledge and have awareness of 
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the presence of lung cancer stigma and the negative ramifications that it has on overall 
QOL, including physical, mental, and social well-being. An evaluation of this health-
related stigma, depression, and QOL should be considered when planning individualized 
care for survivors of lung cancer, particularly African Americans.  
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Introduction 
  Although there have been advances in early detection and treatment modalities, 
lung cancer remains the leading cause of cancer and cancer deaths among both men and 
women in the United States (American Cancer Society [ACS], 2019). In 2018, the ACS 
estimated over 224,000 diagnoses of lung cancer with approximately 142,000 deaths 
from the disease. Individuals living with lung cancer experience greater levels of 
psychological distresses in comparison to other cancer survivors (Brown Johnson et al., 
2015; Chambers, Baade et al., 2015; Chapple, Ziebland, & McPherson, 2004; Gonzales 
& Jacobsen, 2012; Hamann et al., 2014). Psychological challenges such as depression 
and anxiety experienced by survivors may worsen shortness of breath, pain, and insomnia 
as well as lead to social isolation and loneliness (Chambers, Baade et al., 2015). Lung 
cancer stigma (LCS) is a formidable challenge among survivors that may affect many 
aspects of life (Cataldo, et al., 2011; Cataldo, Jahan, & Pongquan, 2012).  
Lung cancer stigma is a complex, intertwining phenomenon associated with the 
behavior of cigarette smoking (Brown-Johnson, Brodsky, & Cataldo, 2014). Cigarette 
smoking is a contributory factor in the development of debilitating chronic diseases and 
is an environmental health hazard (U.S. Department of Health and Human Services 
Public Health Office of the Surgeon General [OSG], 2014). Anti-smoking campaigns 
have resulted in ostracization of smokers who continue this behavior despite the health 
warnings (Bayer, 2008). This characterization occurs in a health-related stigma when 
lung cancer survivors are categorized and viewed with shame and blame (Hamann et al., 
2014). Lung cancer stigma is characterized by negative and victim blaming perceptions 
of cigarette smoking and a lung cancer diagnosis, and verbiage or actions of others that, 
in turn, exacerbate psychological distresses, negatively influence QOL, and contribute to 
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the layered effect of stigma for individuals with lung cancer (American Lung Association 
[ALA], 2014; Daher, 2012; Lebel, Castonguay et al., 2013). This layered stigma affect 
may yield feelings of stigma and shame for lung cancer survivors. It may also contribute 
to social isolation which affects mental and physical symptom burden (Brown-Johnson et 
al., 2014; Carter-Harris & Hall, 2014; Cataldo et al., 2011). 
African Americans experience a significant disparity in lung cancer incidence and 
survival rates. In 2017, there were 24,000 lung cancer diagnoses among African 
Americans and over 17,000 deaths resulting from this disease (ACS, 2016). The overall 
5-year relative survival rate for lung cancer is lower in African Americans in comparison 
to Caucasians: 14% versus 18%, respectively (ACS, 2016). In the state of South Carolina, 
African Americans males have a higher age-adjusted incidence of lung cancer (88%) and 
a lower survival rate (13.4%) compared to Caucasian males (78.8% incidence, 15.5% 
survival rate). By contrast, African American women have a lower age-adjusted lung 
cancer incidence (39%) and survival rate (19.1%) compared to Caucasian women (56.1% 
and 21.6%, respectively) (CDC, 2018). This cancer disparity is disconcerting for the 
African American community.  
Many factors influence lung cancer outcomes among African Americans. Lack of 
access to quality health care resulting in delayed diagnosis, fewer options offered at the 
time of diagnosis, limited treatment choices, and cancer risk behaviors are a few possible 
factors involved with the disparate survival rates (Park et al., 2011). African Americans 
living with lung cancer have higher rates of depressive symptoms than Caucasian lung 
cancer survivors (Traeger, Cannon, Pirl, & Park, 2013). This may be caused in part by 
individuals continuing a behavior that has contributed to the disease state, as well as less 
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compassion and support from others compared to those who contract and live with other 
types of cancer, such as breast and prostate (Traeger et al., 2013). Stigma (perceived or 
experienced, or both) is another variable which negatively impacts this vulnerable 
population of cancer survivors (Cataldo et al., 2011; Chambers et al., 2012; Chapple et 
al., 2004; Gonzales & Jacobsen, 2012; Hamann et al., 2014). Stigma may be influenced 
by individuals attributing a lung cancer diagnosis to cigarette smoking, whereas other 
cancers may be thought to occur by factors outside of a person’s control (Else-Quest, 
LoConte, Schiller, & Hyde, 2009).  
To date, there is limited research on lung cancer stigma among African 
Americans. Investigating the ramifications of lung cancer stigma in this vulnerable 
population will add to the body of knowledge about lung cancer survivorship and provide 
evidence that may assist with development of interventions to mitigate the negative 
influences of stigma and improve survival rates as well as QOL.  
The Cataldo Lung Cancer Stigma Scale (CLCSS), adapted in 2011 from Berger’s 
HIV stigma scale, is the first validated health-related stigma instrument specifically for 
lung cancer survivors (Cataldo et al., 2011). This instrument evaluates perceived stigma 
with four domains: stigma and shame, discrimination, social isolation, and smoking. To 
date, this instrument has demonstrated content and construct validity among primarily 
Caucasian samples in the United States (Brown-Johnson et al., 2014; Cataldo et al., 2011; 
Cataldo et al., 2012; Hamann, Shen, Thomas, Lee, & Ostroff, 2017; Shen, Hamann, 
Thomas, & Ostroff, 2016). To continue to add to the body of evidence related to lung 
cancer stigma, it is warranted that the CLCSS be evaluated among African American 
lung cancer survivors.  
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Study Aims and Hypotheses 
The aims of this study are to evaluate: (1) the internal consistency reliability, and 
construct validity of the CLCSS among African American lung cancer survivors in South 
Carolina, and (2) explore the experiences and interpretations of the CLCSS among this 
sample of survivors of lung cancer. 
The following hypotheses will be tested:  
1. The CLCSS will demonstrate internal consistency among this population of lung 
cancer survivors, with a Cronbach’s alpha of greater than 0.7. 
2. Construct validity will be supported by a positive correlation between lung cancer 
stigma and depressive symptoms and a negative correlation between lung cancer 
stigma and QOL. 
Methods 
This study was guided by an adapted conceptual model of lung cancer stigma 
originally developed by Cataldo et al. (2011). This adapted model posits that lung cancer 
survivors perceive societal attitudes related to smoking and a lung cancer diagnosis. The 
survivor is aware of potential or actual behaviors exhibited by others, and this perception 
prompts certain feelings, such as the feeling of stigma and shame. The perceptions and 
feelings of the survivor are associated with depression, which affects QOL and survival 
rates. (See Figure 3.1.) 
To address the aims, a multiple-method approach was used. Quantitative methods 
included correlational analysis to determine the linear direction and to quantify 
relationships between LCS and depression and LCS and QOL. Concurrently, a qualitative 
62 
approach was used to evaluate the experiences of LCS and the understanding and 
interpretation of the CLCSS amongst this sample. 
Participant Selection, Recruitment, and Ethical Considerations 
Participants were eligible and recruited for the study if they were age 21 years or 
older, had a personal history of lung cancer, could speak and read English, and were an 
African American resident of South Carolina. After Institutional Review Board (IRB) 
approval from the study sites, a purposive sample of 26 African American participants 
was recruited from three sources: a cancer registry of an accredited American College of 
Surgeons cancer program; the Breathe Easier Club, a support group for lung cancer 
survivors; and an ambulatory cancer treatment center. The primary recruitment method 
was an IRB-approved recruitment letter and flyer that were mailed to potential 
participants explaining the purpose and procedure of the study. Over a 4-month period, 
137 invitations were mailed to African Americans survivors of lung cancer, and a 
telephone call followed the mailing within 1–2 weeks. Potential participants had the 
option of having the surveys mailed to them, administered via telephone, or administered 
in person at a convenient location. The secondary recruitment method was a face-to-face 
meeting with survivors who were in attendance at the Breathe Easier Club meeting. The 
third recruitment strategy involved placing recruitment flyers in strategic areas at an 
ambulatory cancer treatment center and approaching survivors during their appointments. 
Each participant received a $20 gift card as a thank you gift. 
Concurrent with quantitative data collection, a subset of the survey respondents 
was recruited to participate in a 30- to 60-minute, semi-structured interview about their 
interpretation of the CLCSS and their experience with LCS. The subset of participants 
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was chosen according to the principle of maximum variation to achieve diversity 
according to their gender, education, lung cancer stage, and time of diagnosis (Creswell, 
2013). Each participant received an additional $10 gift card for completion of the 
interview 
Instruments 
Demographic Characteristics 
All participants completed an investigator-developed demographic form, which 
collected information such as gender, age, annual household income, cancer diagnosis 
year, self-reported health status, smoking status, educational attainment, and employment 
data.  
Stigma  
The CLCSS is a 31-item, 4-point Likert scale that evaluates stigma. The original 
psychometric testing was conducted by Cataldo et al. (2011). Exploratory factor analysis 
identified four domains: stigma and shame, social isolation, discrimination, and smoking. 
The original psychometric testing was conducted on an online sample that consisted of 
primarily Caucasian participants (86%), without African American representation 
(Cataldo et al., 2011). This original psychometric evaluation yielded excellent internal 
consistency (Cronbach’s alpha = .97), and construct validity was determined with 
correlational analysis among similar variables—depression, QOL, anxiety, and social 
isolation (Cataldo et al., 2011). CLCSS scores range from 31 (low stigma) to 124 (high 
stigma).  
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Depression 
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item 
self-report scale. This instrument has shown to be reliable across gender, race, and age 
(Radloff, 1977). It has a high internal consistency, ranging from .85 to .90 (Radloff, 
1977). This nondiagnostic instrument has multiple domains of depression, which include 
depressed mood, feelings of guilt and worthlessness, feelings of helplessness and 
hopelessness, psychomotor retardations, loss of appetite, and sleep disturbance. Scores 
for this instrument are 0 (low depressive symptoms) to 60 (high depressive symptoms). A 
score equal to or above 16 indicates depression. Depression, particularly the feeling of 
guilt, is associated with this lung cancer stigma (Brown-Johnson et al., 2014). 
Quality of Life 
The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core (EORTC QLQ-C30) measures QOL in individuals diagnosed with 
cancer. The 13-item supplement for lung cancer was used for this study. This instrument 
was tested on lung cancer patients and yielded an acceptable internal consistency of .70 
(n = 110). Criterion validity was supported by correlation with clinical parameters that 
addressed all domains of the scale (Nicklasson & Bergman, 2007). This study focused on 
participants’ global health, indicating overall QOL of the cancer survivor. The score 
range was 0 (low global health) to 100 (high global health). The mean global health score 
for individuals with a lung cancer diagnosis is 56.6 (± 24.3). The influence from a health-
related stigma has a negative impact on overall QOL. This is true in the case of lung 
cancer stigma (Cataldo et al., 2011). 
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Quantitative Analysis  
Data were analyzed using SPSS Statistics Version 25.0. ® Descriptive statistics 
were calculated to examine participants’ demographic characteristics and instrument 
scores on LCS, depression, and global health. Global health was calculated using two 
self-reported questions about participants’ health and QOL in the past week, and was 
rated on a 7-item scale (1 = poor health/QOL, 7 = excellent health/QOL). Construct 
validity of the CLCSS was evaluated using correlational analysis, which examined 
association between LCS and depressive symptoms, and between LCS and global health.  
Qualitative Analysis  
Semi-structured interviews were audio-recorded and professionally transcribed 
verbatim. The semi-structured interview guide contained questions designed to elicit 
understanding of the terminology and meaning of the statements of the CLCSS. The PI 
went over each statement of the CLCSS to gain this information (see Figure 3.2). The 
recordings were reviewed for discussion elements and recall. Using an iterative approach, 
two authors (LW, SD) independently coded the full transcripts line by line and searched 
for salient themes. The two then met to compare codes, resolve any differences, and 
identify themes. The researchers categorized the codes according to the CLCSS domains 
and discussed specific quotes that represented the proposed themes. After conducting 10 
interviews, it was determined that data saturation was reached, and the analysis was 
finalized.  
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Results 
Participant Profile 
The survey sample consisted of 26 African Americans (16 females, 10 males). 
Participants’ average age was 67 years (SD = 8.9; range, 48–81). Half of the sample was 
married with some college education. Participants’ lung cancer stages ranged from 1A to 
4B, with over half diagnosed within the past 2 years. Over 60% rated their health as fair 
to poor. Nineteen were former smokers, 4 were current smokers, and 3 never smokers 
(see Table 3.1).  
Of the 26 participants, 10 (6 females, 4 males) were chosen and consented to 
participate in the one-to-one interviews. For this subsample, lung cancer stages ranged 
from 1A to 3B, the average age was 67.3 (range: 62–74), and 40% had at least some 
college education. Eighty percent reported their health as fair, 40% were married, and all 
10 were retired or unable to work. All were former smokers, with number of years of 
smoking ranging from 7 to 30.  
Lung Cancer Stigma, Depression, and Global Health 
Quantitative Results 
The participants reported a mean stigma level of 57.8 (SD = 15.26) with a 
possible range of 31–124, indicating a moderate level of perceived stigma. Cronbach’s 
alpha was reported as .957 with an inter-item correlation mean of .447. The mean 
depressive symptoms level reported was 17.6 (SD = 9.72; range: 0–60), indicating 
moderately high depressive symptoms. The mean score for global health was 63.5 (SD = 
25.61; range: 0–100), indicating modestly high overall QOL. (See Table 3.2.)  
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Descriptive correlational analysis indicated a strong, statistically significant 
positive association between depression and stigma (r = .494, p = .005). However, the 
third hypothesis was not supported. There was a marginally significant negative 
association between QOL and stigma (r = -.292, p = .074). It is important to note that 
there is a significant strong negative association between depression and global health, 
which was not a tested hypothesis but important for understanding the relationship 
between these variables (r = -.746, p = .000). (See Table 3.3.) 
Qualitative Results 
Themes were categorized according to the four CLCSS domains (see Table 3.4). 
The first domain is stigma and shame.  
Theme 1: Not Feeling Guilty, but Regretting Smoking Cigarettes 
In this sample, a few survivors expressed not feeling guilty but regretting ever 
smoking cigarettes. They also thought it possible that others with their condition may feel 
guilty, even though they personally did not feel this way. Here are some representative 
responses:  
“I don’t feel guilty. I don’t know why. I was the one that was diagnosed but I 
don’t feel guilty. I just hate that it happened to me.” 
“So, I knew—why I had cancer. I didn’t feel guilty but there may be other people 
who never smoked and for some reason it bothers them to a guilty point. But I 
can’t see a reason for people feeling guilty.” 
“I don’t feel I deserved cancer. But I realize that if I hadn’t smoked my cancer or 
not having lung cancer or maybe any kind of cancer would have been greater.” 
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Theme 2: Transferring the Blame 
Many interviewed participants expressed some conflicting thoughts about the 
cause of their diagnosis. While they stated that they felt responsible for the development 
of their diagnosis, they also pointed out that lung cancer is also caused by other factors.  
“I personally don’t feel guilty for my— for my lung cancer because there are 
other factors that go into it besides smoking.” 
“I don’t think anybody . . . would feel guilty about having cancer. That’s 
something you can’t control. Um—like, meaning it’s your fault.” 
Interviewed participants (all former smokers) were inconsistent in their views of the 
possible cause of their lung cancer, but all felt strongly that others need to know lung 
cancer can be caused by other factors. This is evident by the following: 
“Lung cancer doesn’t necessarily come from a cigarette. Lung cancer is not a 
cigarette that you put in your mouth. Lung cancer can come from secondhand 
smoke. And, I mean, that’s been said for years, but I guess when people started 
getting cancer that didn’t smoke that’s when they realized that statement to be 
true.” 
“I don’t think that would be [that smoking causes lung cancer] . . . because 
smokers and non-smokers have lung cancer. So, if someone thinks lung cancer is 
only cause by cigarettes—it would just be someone who don’t have clear 
understanding about lung cancer.” 
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Theme 3: Feeling Isolated Because of Physical Limitations 
A few participants expressed feeling social isolation because of their physical 
limitations. Their conditions included shortness of breath, fatigue, and nausea, all of 
which limited their physical functionality.  
“I just don’t go to the things I used to because I don’t dance like I used to. I don’t 
have the strength to do what I used to, and I can’t participate in the activities like 
I used to.”  
“I don’t spend no time around others, not like the way [I] used to—you know, 
spend time there socializing. Well to some extent because I am not able to be out 
there like that now. So, [I] have to walk in a different direction.”  
Theme 4: Thinking Lung Cancer Is a Sentence to Death 
When asked if others have distanced themselves from them because of their lung 
cancer diagnosis, many participants did not indicate having this experience. However, a 
few felt that others with their condition could possibly experience this situation. The 
reason for the distancing, they explained, would be the thought of fatality related to the 
diagnosis of lung cancer. Many of the participants were proud to point out that they were 
surviving their diagnosis: 
“Others may have that perception, that if you get lung cancer then you’re dead. 
Yeah, and that is not the case—I’m living proof.”  
“Cancer usually frightens people that you’re going to die. Not today. We are 
survivors.”  
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Theme 5: Putting Trust in God, Not Worrying About Being Judged by Others  
The domain of discrimination yielded two more themes. Two participants plainly 
stated it this way: 
“At the end of the day, it’s just me and the Lord.”  
“I don’t live my life for others to pick it apart.” 
Theme 6: Lack of Trust/Fairness From Insurance Providers and Employers 
The participants responded to statement related to discrimination from insurance 
companies and employers. From their statements, it was clear that there is a lack of trust 
among these entities.  
“Employers—when I first started out in my career, would judge you as far as 
weight, health problems, and they decide whether they was going to hire you or 
not. Now here we are almost fifty years later, and it hasn’t improved; it’s gotten 
worse.” 
“I know a lot of jobs [where] they don’t have that blanket of protection for you so 
there’s—you kind of like a big loss if you have no benefits to back you up.” 
“Insurance companies are making decisions pertaining to our health depending 
on your pocket.” 
Theme 7: People Believing Lung Cancer Is Caused by Smoking 
 A few participants expressed that some people are more predisposed to lung 
cancer, whether they smoked or not, and regardless of whether they stopped smoking 
months or years prior to diagnosis. However, many participants noted that other people 
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think that if a person has lung cancer, it must mean he or she once smoked or currently 
smokes cigarettes. Many participants made a statement along these lines: 
“Yeah, there’s a lot of people does think it comes from smoking, yes.” 
“People tend to think that if you ever, ever smoked that that’s why you have lung 
cancer.”  
 The authors’ aim was also to understand how African Americans interpreted the 
statements in the CLCSS. This sample of African Americans demonstrated understanding 
of 29 of 31 CLCSS items. The first exception was related to the one item regarding lung 
cancer survivors being viewed as dirty. The other item regarded survivors feeling 
unclean. In both instances the survivors expressed their opinions that uncleanliness is 
related to physical symptoms; they did not think of it as referring to lung cancer as a dirty 
disease related to cigarette smoking. They expressed similar comments about the 
statement about feeling unclean. Participants also expressed concern that others need to 
be educated to understand that lung cancer is not contagious, and they felt some people 
may need education on all the causes of lung cancer.  
Examining Quantitative and Qualitative Data 
Utilizing multiple methods (i.e., collecting quantitative and qualitative data) 
facilitated a deeper interpretation of the CLCSS. Quantitative data generated by the 
instruments and qualitative data generated from the interviews were collected 
concurrently, analyzed separately, and interpreted by combined results (Creswell, 2013). 
These data displayed a moderate level of congruence between the quantitative and 
qualitative data.  
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Discussion 
It was hypothesized that the CLCSS would prove to be a reliable instrument for 
evaluating LCS in this sample of African American lung cancer survivors. The study’s 
findings validate the first hypothesis (CLCSS internal consistency). Even though the 
finding reported that the CLCSS was reliable for evaluating LCS, the instrument is 
lengthy (31 items), and an original Cronbach alpha of .96 indicates redundancy among 
items (Cataldo et al., 2011). Carter-Harris and Hall (2014) shortened the CLCSS to 21 
items (yielded a Cronbach alpha of .93), lessening the burden on participants and 
addressing the redundancies. This revised scale may be useful in future research inquiries 
related to LCS.  
This study evaluated the interpretations of the CLCSS among this sample. There 
were two items the participants did not regard as stigma-related. An example was their 
assumption that cleanliness related to physical symptoms rather than to the societal view 
of cigarette smoking as a “dirty” habit. Although, these were the only two 
misinterpretations of the CLCSS for this sample, there is a possibility that this may 
extend to more statements of the scale among African American survivors of lung cancer. 
This is a very important indication for future research. It is imperative that cultural 
considerations, such as how instrument items are interpreted by African Americans, be 
evaluated to fully understand the lung cancer experience.  
Construct validity of the CLCSS was validated in this study (hypothesis 2). The 
study found a statistically significant positive relationship between LCS and depression 
as well as a statistically significant negative relationship between LCS and QOL. This is 
consistent with previous findings on lung cancer survivors (Cataldo et al., 2011).  
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African American cancer survivors historically have been underdiagnosed, 
misdiagnosed, and undertreated related to depressive symptoms (Traeger et al., 2013). 
This sample experienced a moderately large number of depressive symptoms. Feelings of 
irritability and fatigue were prevalent in this sample. These symptoms overlap with 
physical symptom burden, so it can be difficult to understand their true basis. This may 
play a major factor in the underdiagnosis, misdiagnosis, and undertreatment of depression 
among cancer survivors generally as well as African Americans specifically.  
QOL was measured by self-reported global health, which including ratings of 
quality of health and life. This sample reported a modestly higher health level than the 
referenced mean for survivors of lung cancer. This was an unexpected finding. The 
mixed methods approach assisted with understanding this finding. As displayed in the 
interviews, the participants considered themselves fortunate to be living and thriving. 
They considered their ability to fight this disease a success, and therefore they rated their 
QOL as good to excellent even when their overall health status was fair to poor. The 
study approach allowed the researchers to reach an inference that is strongly validated by 
the combination of statistical data (on global health) and data from the interviews. 
Depressive symptoms and QOL were statistically significant with a negative 
association. This indicates that depressive symptoms and QOL impact each other, and 
their relationship needs evaluation in order to plan and provide appropriate care to 
survivors. It is important to note that QOL can be measured by many variables, 
encompassing physical, social, and spiritual functioning. This sample of cancer survivors 
suffered from multiple-physical-symptom burden, including shortness of breath, 
insomnia, anxiety, and pain. Although these physical and psychological challenges were 
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reported, the sample participants were generous with their overall input by reporting a 
higher QOL level.  
Conclusion 
Lung cancer stigma was moderately experienced by this sample of African 
American lung cancer survivors. This was indicated by the amount of stigma measured 
and reported from the CLCSS as well as from the semi-structured interviews. This 
research approach promoted deeper understanding of how members of this understudied 
population of lung cancer survivors view stigma, while also adding to the larger body of 
evidence regarding lung cancer survivors. An evaluation of stigma, depression, and QOL 
may be warranted when planning individualized care for African American lung cancer 
survivors. More research is needed to develop practical strategies to measure these 
variables. Additional evaluation of cultural considerations is warranted among African 
Americans and the CLCSS. 
Limitations 
To the best of our knowledge, this is the first study focused on African Americans 
and the evaluation of lung cancer stigma. Although this study provides new evidence, it 
represents a small sample in only one region of the United States.  
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Table 3.1 Descriptive Statistics of Demographics and Health Status 
 
Characteristic Categories/description Mean (SD) 
Age Range: 48–81 67.2 
Gender Male 
Female 
10 (38.5) 
16 (61.5) 
Education High school graduate/some 
college 
18 (69.2) 
Work status Retired/unable to work 22 (84.6) 
Self-reported health Fair to poor 17 (65.4) 
Year diagnosed 2016 and after 14 (54.8) 
Smoking status Never smoker 
Current smoker 
Former smoker 
3 (11.5) 
4 (15.3) 
19 (73.2) 
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Table 3.2 Descriptive Statistics for Lung Cancer Stigma, Depression, and Global 
Health/Quality of Life 
 
Instrument Mean 
Standard 
deviation 
Sample 
range 
Possible 
range 
CLCSS 57.8 15.3 35–94 31–124 
CES-D 17.6 9.7 4–37 0–60 
EORTC QLQ-C30 63.5 25.6 0–100 0–100 
Note. CLCSS = Cataldo Lung Cancer Stigma Scale; CES-D = Center for 
Epidemiologic Studies Depression Scale; EORTC QLQ-C30 = European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
Core. 
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Table 3.3 Correlational Analysis with Pearson Product 
 
Measure (Instrument) 
Lung cancer 
stigma (CLCSS) 
Depressive symptoms 
(CES-D) 
Global health, 
QOL (EORTC 
QLQ-C30) 
Lung cancer stigma 
(CLCSS) 
 .494* -.292 
Depressive symptoms 
(CES-D) 
.494*  -.746* 
Global health, QOL 
(EORTC QLQ-C30) 
-.292 -.746*  
Note. CLCSS = Cataldo Lung Cancer Stigma Scale; CES-D = Center for Epidemiologic Studies 
Depression Scale; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire Core; QOL = quality of life.  
*p < 0.005 
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Table 3.4 Themes Categorized by CLCSS Domains 
 
Domain Emerged themes 
Stigma and shame 1) Not feeling guilty but regretting smoking cigarettes 
2) Transferring the blame. 
Social isolation 3) Feeling isolated because of physical limitations 
4) Thinking lung cancer is a sentence to death 
Discrimination 
 
5) Putting trust in God, not worrying about being judged by 
others 
6) Lacking trust/fairness from insurance providers and employers 
Smoking 7) People believing lung cancer is caused by smoking 
Note. CLCSS = The Cataldo Lung Cancer Stigma Scale. 
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Figure 3.1 Proposed Conceptual Model 
 
 
 
Precursors 
• Perceptions of societal attitudes toward smoking and lung cancer 
o Blame 
o Shame 
•   Self-knowledge of having a lung cancer diagnosis 
Perceived Lung Cancer Stigma 
(potential or actual) 
 
Social disqualification—Social 
isolation 
 
Limited opportunities—Discrimination 
 
Internalized Lung Cancer Stigma 
Negative change in identity—stigma 
and shame/smoking   
                       
Self-blame 
Regret 
Guilt 
 
Depression 
Responses 
Quality of Life 
 
Functionality                            Physical 
Role                                          Cognitive 
Emotional                                 Social 
Health Status                            Physical Symptoms 
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1.  I feel guilty because I have lung cancer. 
 What do you think about this statement? 
How do you define “guilty” in this question? 
Is the language understandable to you? 
Do you think that you or someone with your condition may experience this? 
Is there a better way to ask this question?  
2.  People with lung cancer lose jobs when employers learn. 
 What are your thoughts about this statement? 
Even if you are unaware of this happening to anyone with lung cancer, do you think it is possible? 
3. I work hard to keep my lung cancer a secret. 
 What do you think about this statement? 
Is the language understandable to you? 
Do you think that you or someone with your condition may experience this? 
Is there a better way to ask this question?  
4. I feel I’m not as good as others because I have lung cancer. 
 What do you think about this statement? 
What do you think this statement is saying about a person with lung cancer? 
5.  People with lung cancer are treated like outcasts.  
 What do you think about this statement? 
How would you define “outcast”? 
Do you think anyone with lung cancer may feel like an outcast?  
6.    Most people believe a person with lung cancer is dirty. 
 What do you think about this statement? 
Can you tell me the meaning of “dirty” in this statement? 
Do you feel or have any idea if others may feel this way? 
7. Having lung cancer makes me feel unclean. 
81 
 Tell me your thoughts about the words “makes me feel unclean.” 
What does this mean to you? 
8.  I feel set apart, isolated from the rest of the word.  
 What do you think about this statement? 
What does “set apart” mean to you?  
Do you feel that anyone with lung cancer may feel isolated? 
9. Having lung cancer makes me feel like I’m a bad person. 
 Tell me your thoughts about this statement?  
Do you think others with lung cancer may experience this feeling?  
10. Some people who know me have grown more distant. 
 What do you think about this statement? 
What does “grown more distant” mean to you? 
11. I worry about people discriminating against me. 
 What do you think about this statement? 
What does “people discriminating against me” mean to you?  
Why would someone with lung cancer feel this way?  
12. Most are uncomfortable around someone with lung cancer. 
 What do you think about this statement? 
What do you think “uncomfortable around someone with lung cancer” means?  
13. I feel the need to hide the fact I have lung cancer.  
 What do you think about this statement? 
Why would someone with lung cancer feel the need to hide this? 
14. I worry that people may judge me when they learn I have lung cancer. 
 What do you think about this statement? 
Why do you think someone with lung cancer would worry about being judged?  
15. I was hurt how people reacted to learning I have lung cancer. 
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 What do you think about this statement? 
What reaction do you think this statement is talking about?  
16. People I care about stopped calling after learning. 
 What do you think about this statement? 
Do you have any idea why this would occur?  
17. Some told me lung cancer is what I deserved for smoking. 
 What do you think about this statement? 
What are your feelings about another person telling someone with lung cancer this?  
18. People have physically backed away from me. 
 What do you think about this statement? 
What do you think “physically backed away” means?  
19. Some people think it is my fault I have lung cancer. 
 What do you think about this statement? 
20. Stopped socializing with some due to their reactions.  
 What do you think about this statement? 
What does stopping socializing mean to you? 
21. Have lost friends by telling them I have lung cancer. 
 What do you think about this statement? 
What are your feelings about lung cancer survivors losing friends after they find out about the 
diagnosis?  
22. People seem afraid of me because I have lung cancer. 
 What are your thoughts about people’s fear of someone with lung cancer?  
23. Older people are less likely than younger people to be blamed for having lung 
cancer. 
 What do you think about this statement? 
Why would an older person have less blame than a younger person?  
24. Health-care providers don’t take “smoker’s cough” seriously.  
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Figure 3.2 Interview Guide 
 
 What do you think about this statement? 
What are your thoughts about a provider who doesn’t take this cough seriously?  
25. People avoid you because lung cancer is associated with death. 
 What do you think about this statement? 
Tell me what your feelings are about someone with lung cancer being alone. 
26. My lung cancer diagnosis was delayed because my health-care provider did not 
take my “smoker’s cough” seriously. 
 What do you think about this statement? 
Do you think this could occur with a person with lung cancer, and if so, why?  
27. I put off going to the doctor because I was afraid. 
 Please tell me how you feel about this statement. 
28. Smokers could be refused treatment for lung cancer. 
 What do you think about this statement? 
Tell me if you think that this could happen and why. 
29. Others assume that a patient’s lung cancer was caused by smoking even if he 
or she had stopped smoking years ago. 
 Please tell me your thoughts on this statement. 
30. Others assume that a patient’s lung cancer was caused by smoking even if he 
or she never smoked. 
 Tell me your thoughts on this statement. 
31. Lung cancer is viewed as a self-inflicted disease.  
 What do you think about this statement? 
Please tell me your meaning of self-inflicted.  
 Are there any more questions or areas that you think need to be asked?  
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CHAPTER 4: 
STIGMA AMONG LUNG CANCER SURVIVORS IN SOUTH CAROLINA3 
                                                 
3 Webb, L. A., McDonnell, K. K., Adams, S. A., Davis, R. E., and Felder, T. M. To be submitted to the 
European Journal of Oncology Nursing.  
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Abstract 
 
Purpose:  
The study aimed to evaluate stigma among survivors of lung cancer. The Cataldo 
Lung Cancer Stigma Scale (CLCSS) was used to assess stigma and its relationship with 
race, depression, and quality of life (QOL) among survivors of lung cancer in South 
Carolina.  
Methods:  
An adapted conceptual model derived from the CLCSS guided this descriptive 
correlation study. Self-reported, written surveys measuring depression, QOL, and lung 
cancer stigma, plus an investigator-developed demographic information form, were 
administered to lung cancer survivors in South Carolina. Statistical analysis was 
conducted to assess associations/relationships between stigma and depression, stigma and 
QOL, and stigma and race, adjusting for demographic characteristics.  
Results:  
Participants (n = 56) included 30 Caucasian and 26 African American survivors of 
lung cancer recruited from a cancer registry of an American College of Surgeons–
accredited program, a support club for survivors of lung cancer, and a private ambulatory 
oncology practice, all near Columbia, South Carolina. Statistical analysis yielded (1) a 
significant moderate positive association between depression and lung cancer stigma, (2) 
a significant moderate negative association between QOL and lung cancer stigma, and (3) 
significant relationships between race and lung cancer stigma. 
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Conclusion:  
Lung cancer stigma affects many aspects of lung cancer survivors’ lives. Health-
care professionals need to consider how this health-related stigma may further complicate 
physical burdens, psychological distresses, and social challenges that accompany the 
disease. Further inquiry and intervention development are needed to assist with 
mitigating the negative effects of lung cancer stigma on survivors and their family 
members and friends.  
  
87 
Introduction 
Lung cancer is the second most prevalent cancer in men and women and the 
leading cause of cancer deaths in the United States (American Cancer Society [ACS], 
2019). The lung cancer incidence and mortality rate have declined due to early screening 
and improved treatment modalities (ACS, 2019; de Moor et al., 2013). However, the 
disease remains a major concern because of its far-reaching negative effects on survivors’ 
overall quality of life (QOL) (Brown-Johnson et al., 2015; Chambers, Baade et al., 2015; 
Chambers et al., 2012; Chapple, Ziebland, & McPherson, 2004; Gonzales & Jacobsen, 
2012; Gonzalez et al., 2015; Hamann et al., 2014; Houlihan & Tyson, 2012). Survivors of 
lung cancer, defined from the time of diagnosis to the end of life, experience significant 
physical symptom burden, social challenges, and psychological distresses (Houlihan & 
Tyson, 2012; Institute of Medicine [IOM] & National Research Council [NRC], 2006).      
A challenge that survivors of lung cancer may face is stigma related to their 
diagnosis. Stigma is an “undesirable stereotype leading people to reduce the bearer from 
a whole and usual person to a tainted, discounted one” (Goffman, 1963). A health-related 
stigma is the perception of a trait that is considered unfavorable and yields an adverse 
result. In the case of lung cancer, the health-related stigma is the perception that an 
individual with lung cancer has smoked or currently smokes cigarettes because tobacco is 
the leading cause of lung cancer (Brown-Johnson, Brodsky, & Cataldo, 2014; Cataldo, 
Jahan, & Pongquan, 2012; Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011; 
Chambers, Baade et al., 2015; Rauma, Sintonen, Räsänen, Salo, &Ilonen, 2015; Rowland 
et al., 2016).  
United States Surgeon General reports have documented strong evidence that 
tobacco is an individual and environmental health hazard (U.S. Department of Health and 
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Human Services Public Health Office of the Surgeon General [OSG], 2014). These 
reports have heightened public awareness of the links between chronic and debilitating 
disease processes and the behavior of cigarette smoking. Public awareness of the hazards 
of smoking has led to the thought that this behavior is an unacceptable “choice” and no 
longer a societal norm (Bayer, 2008). This leads to the ostracization of smokers and to 
victim blaming of those who formerly or currently smoke despite its known hazards.  
Lung cancer stigma’s layered effect on survivors impacts all aspects of their lives. 
Survivors have reported feelings of social isolation and discrimination from friends and 
family related to their diagnosis (Cataldo et al., 2011; Hamann et al., 2014; Shen et al., 
2015). Some survivors reported a reluctance to share their diagnosis and experiences with 
others due to fear of their reactions (Webb & McDonnell, 2018). This alienation further 
amplifies the influence of stigma and negatively affects psychological distress that they 
may be experiencing. This effect of stigma also intensifies the burden of physical 
symptoms such as shortness of breath, fatigue, insomnia, and pain—which, in turn, 
negatively impact lung cancer survivors’ ability to deal with psychological and social 
challenges in addition to adversely affecting their overall QOL (Gonzalez & Jacobsen, 
2012). The lack of physical, mental, and social well-being majorly hampers survivors’ 
ability to manage physical symptom burden and to cope with social and mental 
challenges—creating a vicious cycle. All of these factors ultimately influence overall 
QOL and survival (Brown-Johnson et al., 2014; Cataldo et al., 2012; Cataldo et al., 2011; 
Chambers, Baade et al., 2015; Rauma et al., 2015; Rowland et al., 2016).  
In 2011, the Cataldo Lung Cancer Stigma Scale (CLCSS) became the first 
psychometrically tested instrument specifically designed to assess lung cancer stigma. 
89 
The original psychometric testing was conducted on an online sample primarily 
consisting of Caucasian participants (86%); no African Americans were represented in 
the testing (Cataldo et al., 2011). This original evaluation yielded great internal 
consistency (a Cronbach’s alpha of .97), and construct validity was determined with 
correlational analysis among similar variables: depression, QOL, anxiety, and social 
isolation (Cataldo et al., 2011). Since 2011, the CLCSS has been used in more racially 
diverse samples. However, the African American representation in those studies was still 
low, thus limiting knowledge related to lung cancer stigma among this vulnerable 
population of lung cancer survivors (Carter-Harris & Hall, 2014; Carter-Harris, Hermann, 
Schreiber, Weaver, & Rawl, 2014; Chambers, Morris  et al., 2015; Chambers, Baade et 
al., 2015; Shen, Hamann, Thomas, & Ostroff, 2016).  
Lung cancer mortality is highest among African Americans in comparison to their 
Caucasian counterparts (ACS, 2019). Given this disparity, a sample with greater African 
American representation would add to the knowledge of lung cancer stigma and overall 
QOL for all lung cancer survivors. South Carolina, ranked 16th in lung cancer incidence, 
has a larger age-adjusted incidence of lung cancer diagnoses in comparison to the 
national rate; this disparity is especially great among males (84.4% in South Carolina vs. 
71.3% nationally) compared to females (53.5% in South Carolina vs. 52.3% nationally) 
(ACS, 2019). South Carolina is considered a rural state with a racial make-up of 
approximately 68% non-Hispanic Caucasians, 28% non-Hispanic African Americans, 
and 5% Hispanic Latinos (United States Census Bureau, 2017). The African American 
age-adjusted incidence of lung cancer in South Carolina is 93.4% in comparison to a 
79.3% incidence among Caucasians in the state. The death rate for African Americans 
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with lung cancer in South Carolina is also higher than the death rate for Caucasians 
(74.9% vs. 62.2%, respectively) (ACS, 2016). This disparate rate is multifactorial and 
warrants inquiry to gain a better understanding of lung cancer survivorship among South 
Carolinians and among African American lung cancer survivors.  
To date, no study has examined lung cancer stigma among lung cancer survivors 
in South Carolina. The purpose of this study is to evaluate stigma among lung cancer 
survivors in the state, with equal representation of Caucasians and African Americans. 
The aims of this study are to (1) evaluate the reliability and construct validity of the 
CLCSS on a purposive sample of Caucasians and African Americans in South Carolina 
with a history of lung cancer, stages Ia–IV; (2) calculate and compare levels of stigma, 
depression, and QOL among demographic variables, gender, race, marital status, 
educational attainment, income status, self-reported health status, and smoking status; 
and (3) evaluate the relationship between race and lung cancer stigma, adjusting for 
demographic variables. 
The following hypotheses will be tested: 
5. The CLCSS will demonstrate internal consistency among this population of 
lung cancer survivors, with a Cronbach’s alpha of greater than 0.7. 
6. There will be a statistically significant positive association between lung 
cancer stigma and depressive symptoms. 
7. There will be a statistically significant negative association between lung 
cancer stigma and QOL.  
8. There will be a statistically significant relationship between lung cancer 
stigma and race, adjusting for demographic variables. 
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Methods 
Design 
This study used descriptive and inferential analysis to analyze and quantify 
relationships between independent demographic variables and lung cancer stigma, 
depression, and QOL. To evaluate the linear relationship of stigma relative to dependent 
variables, correlation analysis was used. To evaluate the relationship between lung cancer 
stigma and race and the remainder of the demographic characteristics, a standard multiple 
regression analysis was used.  
Conceptual Framework 
Based on the conceptual model of lung cancer stigma proposed by Cataldo et al. 
(2011), this research will be guided by the principal investigator’s (PI’s) adapted model. 
This model posits that lung cancer survivors perceive societal attitudes relative to 
smoking and a lung cancer diagnosis. Survivors are aware of potential or actual behaviors 
exhibited by others and by feelings that may occur because of this perception. This may 
lead to feelings that negatively change their identity to one of stigma and shame. The 
perceptions and feelings of survivors are associated with depression and QOL and 
therefore affect survival rates. (See Figure 4.1.)  
Design  
This study used descriptive correlational analysis to analyze and quantify 
relationships between independent demographic variables and lung cancer stigma, 
depression, and QOL. To evaluate directional association relative to dependent variables, 
correlation analysis was used. To evaluate the relationship between lung cancer stigma 
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and the demographic characteristics, (race, marital status, smoking status, and self-
reported health status), a standard multiple regression analysis was used.  
Participant Selection, Recruitment, and Ethical Considerations 
The institutional review boards (IRBs) of the University of South Carolina (USC) 
and Palmetto Health (PH) in Columbia, South Carolina, approved this research. 
Participants were eligible for the study if they were 21 years of age or older, had a 
personal history of lung cancer, could speak and read English, and resided in South 
Carolina. The primary recruitment method was an IRB-approved recruitment letter and 
flyer describing the purpose and procedure of the study. The letter and flyer were mailed 
over a 4-month period (May–August 2018) to 500 potential participants who were 
identified by a cancer registry from a local cancer center accredited by the American 
College of Surgeons. A follow-up telephone call was made to potential participants 
within 1–2 weeks of mailing the printed materials. Potential participants had the option of 
having the surveys mailed to them, administered by the PI via telephone, or administered 
by the PI in person at a convenient location. A secondary recruitment method took place 
at a meeting of the Breathe Easier Club, a support club for lung cancer survivors in 
Columbia, South Carolina. This club provided the opportunity to meet potential 
participants face-to-face. After the club meeting, potential participants were given the 
opportunity to participate in the research. A third and final recruitment effort occurred at 
a large, private ambulatory oncology practice in Columbia, South Carolina. IRB-
approved flyers were placed in strategic areas at this practice, and face-to-face 
introductions of the study were made to lung cancer survivors during their scheduled 
appointments. Participants had the opportunity to participate upon completion of their 
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appointment. Informed consent was obtained prior to participation, and upon completion 
of the survey, each participant received an appreciation gift (a gift card to a local retail 
store).  
Instruments 
Demographic Characteristics  
The PI developed a demographic form to collect information about each 
participant, including gender, age, annual household income, year of cancer diagnosis, 
self-reported health status, smoking status, educational attainment, and employment data.  
Stigma 
The CLCSS is a 31-item, 4-point Likert scale that evaluates stigma. The original 
psychometric testing was conducted by Cataldo et al (2011). Exploratory factor analysis 
identified four domains: stigma and shame, social isolation, discrimination, and smoking. 
Reliability was established by a coefficient alpha of 0.96 for the entire scale. Construct 
validity was supported by association with the related constructs of self-esteem, 
depression, social support, and social conflict. CLCSS scores range from 31 (low stigma) 
to 124 (high stigma).  
Depression  
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item, 
non-diagnostic, self-report scale. The instrument domains of depression include 
depressed mood, feelings of guilt and worthlessness, feelings of helplessness and 
hopelessness, psychomotor retardations, loss of appetite, and sleep disturbance (Radloff, 
1977). This instrument has shown to be reliable across gender, race, and age, and it has a 
high internal consistency, ranging from 0.85 to 0.90 (Radloff, 1977). Scores for this 
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instrument range from 0 (indicating low depressive symptoms) to 60 (high depressive 
symptoms).  
Quality of Life  
The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core (EORTC QLQ-C30) measures QOL in individuals with a cancer 
diagnosis. This scale was tested on lung cancer patients and yielded an acceptable 
internal consistency of 0.70 with a sample size of 110. Criterion validity was supported 
by correlation with clinical parameters that addressed all domains of the instrument 
(Nicklasson & Bergman, 2007). A 13-item supplement specifically for lung cancer was 
also used for this study. This study focused on the global health of the cancer survivor. 
The score range was 0 (low global health) to 100 (high global health), where 56.6 is the 
mean for lung cancer survivors.  
Data Analysis 
Data were analyzed using SPSS Statistics Version 25.0®. Descriptive statistics 
were calculated to describe the sample. The CLCSS was reverse-scored and averaged. 
The CES-D was scored and averaged according to the Center for Epidemiologic Studies’ 
guidelines. QOL was calculated by applying linear transformation to two global health 
questions (representing participant QOL). Construct validity of the CLCSS was evaluated 
using correlational analysis, which examined the linear relationship between lung cancer 
stigma and depressive symptoms, and between lung cancer stigma and global health. A 
general linear model analysis was conducted on lung cancer stigma and race, and the 
remainder of the demographic characteristics. Factor and covariates model effects were 
applied using the general linear model option in SPSS. Race was modeled as the primary 
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effect with other demographic variables (individually), with lung cancer stigma as the 
dependent variable. Using an alpha cutpoint of .05 from the bivariable models (race plus 
one demographic variable at a time), we determined the covariates that may significantly 
confound the relationship between race and stigma. The final model included race and 
any other independent variable that demonstrated a significant relationship. Significance 
in the final linear model was determined at p < .05. 
Results 
Participant Profile 
The original sample included 62 individuals. Fifty out of the 62 participants were 
recruited from the 500-member cancer registry direct mailing. Of the 500 direct mailings, 
48 were returned and 178 of recipients were unable to be contacted. The remaining 12 
participants were recruited from a meeting of the support club and the private oncology 
practice. Six participants did not complete all of the requested survey material and 
therefore were excluded from the data analysis. Of the 56 participants included in 
analysis, 30 were Caucasians (54%) and 26 were African Americans (46%). Participant 
ages ranged from 48 to 81 years with a mean of 67 (SD = 8.9). Over half of the sample 
was married with some college education. Participants’ lung cancer stages ranged from 
IA to IV, with over half of participants diagnosed within the past 2–3 years. Over 50% 
rated their health as fair to poor. The sample included 43 former smokers, 7 never 
smokers, and 6 current smokers (see Table 4.1).  
Statistical Analysis 
The CLCSS had a Cronbach’s alpha of .96, indicating very good internal 
consistency. Correlational analysis displayed a statistically significant moderate positive 
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association between stigma and depression (r = .345, p = .005) and a statistically 
significant moderate negative association between stigma and QOL (r = -.303, p = .012). 
This supports hypotheses 1, 2, and 3 (see Table 4.2). The average instrument scores were 
as follows: lung cancer stigma, 51.38 + 16.32; depression, 15.84+ 10.22; and QOL, 62.68 
+ 24.04. The average stigma score for Caucasian participants was 45.2 + 14.95, while for 
African American participants the average was higher at 58.5 + 15.09. The independent t-
test displayed a t value of -3.3 (p = .002), and an eta-squared of 16%, indicating that race 
had a large effect on the mean stigma score. Race and gender were found to be 
insignificantly related to overall depression and QOL (see Table 4.3). Participants who 
were married displayed the lowest lung cancer stigma score on average (47.45 + 14.77); 
by comparison, participants who were single had an average score of 68.2 + 14.97. This 
finding was statistically significant, with a large effect related to marital status (p = .033, 
η2 = 0.17). Marital status was also found to have a statistically significant relationship to 
QOL. On average, participants who were single displayed a higher QOL (84.8 + 17.22) 
than participants who were separated or divorced (50.45 + 23.69). This was shown to be 
significant statistically, with a large effect attributed to marital status (p = .039, η2 = .17). 
A generalized linear model was used to evaluate relationships among demographic 
variables and lung cancer stigma. The final model consisted of race and income. Race 
was found to have the strongest relationship to lung cancer stigma (p = .002) and income 
demonstrated a relationship as well (p =.012). The estimated marginal mean for lung 
cancer stigma for Caucasians was 48.05; for African Americans it was 60.03. (See Table 
4.4.) 
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Discussion 
Evaluation of the CLCSS 
In this study, the CLCSS was found to be a reliable and valid instrument among 
this sample of lung cancer survivors. This 31-item instrument displayed a Cronbach’s 
alpha of .96, which indicates good internal consistency, but also possible redundancy of 
items. Carter-Harris and Hall (2014) developed a shortened version of the CLCSS. That 
shorter version consisted of 21 items and displayed a Cronbach’s alpha of .93, indicating 
very good internal consistency. Further investigation with this revised shortened 
instrument is warranted and will continue to add to existing knowledge of lung cancer 
stigma. It’s possible the shortened version will be more widely accepted in clinical 
practice, as it may lessen the time and burden on survivors who complete it.  
Relationship of Stigma to Depression and QOL 
Lung cancer survivors experience great psychological distresses. This study 
presents statistically significant findings of a moderate positive association with 
depression. Depressive symptoms are prevalent among those living with lung cancer, and 
depression is considered one of the most prominent psychological challenges for this 
population (Brown-Johnson et al., 2014; Cataldo et al., 2012; Chambers et al., 2012; 
Gonzalez & Jacobsen, 2012). In their study (N = 190), Cataldo et al. (2012) found that 
increased depression was strongly associated with increased stigma, and that depression 
was secondary to lung cancer stigma in impact on QOL. The two variables together 
explain most of the variance with QOL. It is imperative to consider the interaction of 
depression and stigma and how it may negatively impact social challenges and physical 
symptoms, and thereby negatively affect QOL. This is especially important among 
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African American cancer survivors because depression is frequently underdiagnosed, 
misdiagnosed, and undertreated (Traeger, Cannon, Pirl, & Park, 2013). Untreated 
depression is likely to further negatively impact all areas of life, potentially leading to an 
inability to manage physical symptom burden and impeding the adoption of health 
behaviors that can help improve overall QOL (McDonnell et al., 2019).  
QOL is multifaceted and can have a direct influence on survival rates of cancer 
survivors (Montazeri, 2009). This study demonstrated that lung cancer stigma has a 
significantly moderate negative association with QOL. Chambers et al. (2012) found that 
lung cancer stigma had an adverse effect on overall QOL in their systematic review. 
Cataldo et al. (2012) had the same finding and indicated that stigma was a major 
contributor to the variance of QOL. Given that survival rates are increasing among lung 
cancer survivors, it is essential to consider the effect of lung cancer stigma, including the 
effect it has on overall QOL along with daily challenges faced by these individuals.  
African Americans on average experienced greater amounts of lung cancer stigma 
and depression. Race significantly contributed to the variance in lung cancer stigma 
experience. Interestingly, average overall QOL among African Americans was higher 
than Caucasians in this study. This may be due, at least partly, to how QOL is calculated 
with this particular instrument. The two weighted questions situated toward the end of the 
instrument focus on overall health and overall QOL within the past week. This can create 
a wide variation in the interpretation of the questions and thus in responses. African 
American participants in this study gave a higher score for QOL despite their high 
physical symptom burden in comparison to Caucasian participants. This was an 
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unexpected finding. Further inquiry and exploration would generate better understanding 
of this finding. 
Demographic characteristics displayed some important associations with the three 
dependent variables of stigma, depression, and QOL. As previously noted, race was 
significantly associated with stigma and depression. However, other characteristics—
such as gender, educational attainment, employment status, and self-reported health 
status—did not have a significant relationship to stigma, depression, or QOL. Although 
there was no significant finding on smoking status and its relationship to stigma, 
depression, or QOL, the never smokers in the study did, on average, display a lower lung 
cancer stigma score in comparison to current and former smokers. This finding is similar 
to those reported by Cataldo et al. (2012). Marital status displayed a significant 
relationship with stigma, depression, and QOL in the correlational analysis. Participants 
who were single displayed a higher level of stigma and QOL and a low level of 
depressive symptoms, whereas divorced or separated participants reported a higher level 
of depression. Interestingly, marital status was not related to stigma in the multiple 
regression. Income level, on the other hand, was found to be significantly related to 
stigma, almost equally to race. The Caucasians in this sample had an average stigma 
score 10.8 points lower than the African Americans, indicating an overall lower 
experience of stigma on average. Individuals in this sample whose income was above 
$20,000 annually had a lower stigma score of 11.1 (on average) in comparison to 
individuals earning under $20,000 annually, which is considered poverty level for a 
household of three people (U.S. Department of Health and Human Services, 2019). A 
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lower socioeconomic status, race, education, and geographic location are variables that 
indicate risk for cancer disparity (Dixit et al., 2016; Singh & Jemal, 2017).  
For lung cancer survivors within our sample, race and income displayed a 
relationship to lung cancer stigma. This is especially noteworthy due to the geographical 
location in which the sample was obtained—South Carolina. This may be due in part to 
the higher rates of smoking in the state, which may be linked to South Carolina’s relaxed 
smoking policies. South Carolina is ranked 14th in the United States for prevalence of 
smoking. Eighteen percent of both Caucasians and African Americans in the state smoke 
cigarettes, while 30% of these individuals earn less than $25,000 yearly per household. 
Among African Americans our sample exhibited higher average levels of lung cancer 
stigma. African Americans historically have experienced negative associations with 
discrimination, which substantially correlates with being stigmatized (Dixit et al., 2016). 
The perception of stigma and discrimination can lead to depression, anxiety, social 
isolation, delayed medical care, and altered patient-provider communication (Brown-
Johnson et al., 2014; Carter-Harris & Hall, 2014; Carter-Harris et al., 2014; Cataldo et al., 
2012; Chamber et al., 2015; Gonzalez & Jacobsen, 2012). 
There are many research foci that lung cancer scientists need to consider. Further 
research is particularly needed in the area of African American lung cancer survivors. 
This study indicates that African Americans have higher levels of stigma. Additional 
investigation of lung cancer stigma is needed in this population to assist with 
development of interventions to alleviate this burden. Although it is well known that 
socioeconomics is a factor in cancer disparity, multilevel interventions are needed to 
assist with alleviating this disparity and lung cancer stigma among lung cancer survivors.  
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Future research should focus on promoting healthy relationships and support 
systems for lung cancer survivors. Additionally, consideration should be given to dyad 
research and to developing interventions aimed at decreasing stigma and depression 
while increasing overall QOL.  
Conclusion 
Lung cancer stigma affects many aspects of the lives of lung cancer survivors. It 
is imperative that health-care professionals take into consideration factors, such as 
socioeconomics and race, known to negatively influence cancer disparities among lung 
cancer survivors. These factors and the effect that lung cancer stigma has on lung cancer 
survivorship further complicates physical burdens, psychological distresses, and social 
challenges. 
Strengths and Limitations 
African American lung cancer survivors experience a cancer disparity nationwide 
and in the state of South Carolina. It is vital to increase participation of this vulnerable 
population of cancer survivors in lung cancer studies. Carter-Harris et al. (2014) 
conducted a lung cancer stigma study with only 17% African Americans while Shen et al. 
(2016) had 14% representation of African Americans in their study. To the authors’ 
knowledge, this is the first study evaluating lung cancer stigma with nearly 50% 
representation of African Americans among a population of lung cancer survivors. The 
findings of this study confirm the known disparity. These findings will add to the 
knowledge of lung cancer stigma for all lung cancer survivors but particularly African 
Americans.  
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There are several limitations to this study. The sample size of 56 was small for a 
descriptive correlational study. In addition, participants were recruited from a cancer 
registry, a support club, and an ambulatory outpatient clinical practice in close proximity 
to one another. Lung cancer survivors in this region may differ from other survivors in 
other areas of the state, country, or internationally. Future studies should focus on 
participants who are representative globally, with an emphasis on adequate representation 
of African Americans and other vulnerable populations worldwide.  
  
103 
Table 4.1 Sample Demographic Characteristics 
 
 
Variable Possible values Self-reported results 
Age  M = 68.11/SD = 9.451 
(Range: 45–89) 
Gender  Male n = 19 (34%) 
Female n = 37 (66%) 
Race Caucasian n = 30 (54%) 
African American n = 26 (46%) 
Marital 
status 
Single n = 5 (9%) 
Married n = 31 (55%) 
Separated/divorced n = 11 (20%) 
Widowed n = 9 (16%) 
Education Some high school n = 7 (13%) 
High school graduate or GED n = 10 (18%) 
Some college (13 years) n = 22 (39%) 
College (4 years or more) n = 16 (29%) 
Employment 
status 
Employed for wages n = 6 (11%) 
Self-employed n = 2 (4%) 
Out of work < 1 year n = 2 (4%) 
Out of work > 1 year n = 3 (5%) 
Homemaker n = 1 (2%) 
Retired n = 27 (48%) 
Unable to work n = 15 (27%) 
Annual 
household 
income 
< $5,000 n = 1 (2%) 
$5,000–$9,999 n = 6 (11%) 
$10,000–$19,999 n = 8 (14%) 
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$20,000–$49,999 n = 23 (41%) 
$50,000–$100,000 n = 9 (16%) 
> $100,000 n = 6 (11%) 
Not reported n = 3 (5%) 
Health 
status 
Excellent n = 2 (4%) 
Very good n = 6 (11%) 
Good n = 18 (32%) 
Fair n = 21 (37%) 
Poor n = 9 (16%) 
Year of lung 
cancer 
diagnosis 
2016 or after n = 30 (48%) 
2015 n = 13 (21%) 
2014 n = 2 (3%) 
2013 n = 2 (3%) 
2012 n = 1 (2%) 
2011 n = 7 (11%) 
2010 or prior n = 7 (11%) 
Smoking 
status 
Never smoker n = 7 (12%) 
Former smoker n = 43 (77%) 
Current smoker n = 6 (11%) 
Note. Some categories may not sum to 100% due to rounding. 
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Table 4.2 Correlational Analysis with Pearson Product 
 
 
  
Measure (Instrument) 
Lung cancer 
stigma 
(CLCSS) 
 
Depressive 
symptoms 
(CES-D) 
Global 
health/ QOL 
(EORTC 
QLQ-C30) 
Lung cancer stigma 
(CLCSS) 
 
 
.345** -.303* 
Depressive symptoms (CES-
D) 
.345** 
 
 -.523** 
Global health/QOL (EORTC 
QLQ-C30) 
-.303* 
 
-.523**  
  *p =.01 
**p = .05 
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Table 4.3 Independent T-test and One Way Anova 
 
Demo-
graphic 
Variables 
Values 
Mean/SD 
Stigma 
(CLCSS) 
Depression 
(CES-D) 
Global Health/ 
QOL 
(EORTC QLQ-
C30) 
Overall   51.38/16.32 16.3/11.8 62.68/24.03 
Race Caucasian  45.2/14.96* 15.43/13.55 61.67/22.89 
African American  58.5/15.10* 17.31/9.57 63.85/25.71 
Gender Male  51.36/17.30 13.53/8.67 59.53/28.55 
Female  51.37/16.04 17.73/13 64.30/21.62 
Marital 
status 
Single  68.2/14.97* 12.8/12.55 84.8/17.22* 
Married  47.45/14.77 16.71/13.13 62.90/21.69 
Separated/ 
divorced  
58.28/14.92 20.09/7.18* 50.45/23.69 
Health 
status 
Excellent 50/26.87 13/9.90 58/11.31 
Very good 46.17/13.15 9.33/8.57 88.5/8.52 
Good 45.5/17.54 15.72/15.96 68.6/14.72 
Fair 56.24/15.02 18.81/8.59 58.09/24.78 
Poor 55.56/15.33 17/10.81 45.33/30.61 
Smoking 
status 
Current 52.67/22.21 17.17/9.95 59.5/27.91 
Former 52.47/16.04 16.84/12.31 61.35/24.49 
Never 43.57/12.2 12.28/10.61 73.57/16.10 
*p < .05 
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Table 4.4 Lung Cancer Stigma: Adjusted Mean for Caucasians and African Americans 
 
Independent Variable 
Adjusted Mean 
Caucasian 
African 
American 
p-value 
Race 48.05 60.03 .002 
    
Note: Adjusted for gender, marital status, educational attainment, work status, self-
reported health, time of diagnosis, and smoking status.  
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Figure 4.1 Proposed Lung Cancer Stigma Model 
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•   Self-knowledge of having a lung cancer diagnosis 
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Limited opportunities—Discrimination 
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Self-blame 
Regret 
Guilt 
 
Depression 
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Quality of Life 
 
Functionality                            Physical 
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Emotional                                Social 
Health Status                            Physical Symptoms 
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CHAPTER 5: CONCLUSION 
Overview of This Study 
 This study evaluated lung cancer stigma among survivors of lung cancers in South 
Carolina. In comparison to previous studies evaluating lung cancer stigma, the difference 
in this study was the sample—specifically, its racial composition. This study’s sample 
consisted of 46% African Americans and 54% Caucasians—to date, this is the first study 
of this kind to recruit an equal representation of Caucasian and African American 
survivors of lung cancer. The rationale for recruiting this sample stems from the cancer 
disparity experienced among African Americans living with lung cancer and the lack of 
existing evidence relative to lung cancer stigma in this underrepresented population. To 
address this disparity, equal percentages of African American and Caucasian participants 
were warranted to facilitate comparisons and foster deeper understanding of lung cancer 
stigma among survivors of lung cancer who are African Americans. The study also had 
the effect of adding to the overall body of evidence related to survivors of lung cancer.  
 Lung cancer stigma impacts many different aspects of the life of a lung cancer 
survivor. The proposed conceptual model of lung cancer stigma illustrates the 
relationships among lung cancer stigma, depression, and overall quality of life (QOL). 
Depression is a psychological challenge experienced by many survivors of cancer, 
particularly lung cancer. Depression can be a reflective experience in stigma and 
manifested as shame, isolation, and discrimination (Brown-Johnson, Brodsky, & Cataldo, 
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2014). In addition to its intertwining relationship with stigma, underdiagnosed, 
misdiagnosed, and undertreated depression can lead to adverse alterations in QOL 
relative to physical and emotional manifestations. The associations among these 
constructs are imperative to evaluate. The experience of lung cancer stigma can increase 
depressive symptoms and decrease QOL, impacting survival rates among this population 
of cancer survivors. Therefore, it was our purpose to evaluate stigma via the Cataldo 
Lung Cancer Stigma Scale (CLCSS) and these related constructs among African 
American and Caucasian South Carolinians living with lung cancer. 
Quantitative and Qualitative Data: Chapter Three 
 A multiple-methods approach was used. The quantitative data of this study 
provided important findings related to lung cancer stigma. Chapter three presents data 
and results of the African American participants. This is the first study in which African 
American survivors of lung cancers were evaluated relative to lung cancer stigma. This 
study’s findings indicate that the CLCSS had excellent internal consistency reliability, 
with a Cronbach’s alpha of .957. The CLCSS was the chosen instrument for evaluating 
lung cancer stigma because it was adapted from Berger and colleagues’ (2001) HIV 
Stigma Model, which was utilized among African Americans with HIV and had 
demonstrated good internal consistency among this population (Buseh, Kelber, Hewitt, 
Stevens, & Park, 2009). Construct validity was determined by the significant positive 
association between lung cancer stigma and depression along with the negative 
association between lung cancer stigma and QOL. These findings were consistent with 
previous research findings with either no representation or a smaller representation of 
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African Americans (Brown-Johnson et al., 2014; Cataldo, Jahan, & Pongquan, 2012; 
Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011).   
These findings indicate that the CLCSS is a reliable instrument for evaluating 
lung cancer stigma among both races. However, the qualitative data presented in this 
study leaves to question if this is truly accurate. There were two items in the CLCSS that 
were misinterpreted; both related to the intended meaning, thereby identifying that 
cultural considerations influence the accuracy of instruments and the constructs they 
measure. In view of the two misinterpreted items for this sample of African American 
survivors of lung cancer, we must consider that this may extend beyond the two items 
when given the opportunity to evaluate other African American survivors. Careful 
attention is warranted when utilizing instruments to evaluate cultures for both clinical and 
research settings.  
Evaluating the qualitative data generated a deeper understanding of the experience 
of lung cancer stigma from the perspective of African Americans and contributed to the 
rigor and robustness of the data (Creswell, 2013). The African Americans in this study 
reported a moderately high level of stigma and depression. They also reported a higher 
QOL than expected. The semi-structured interviews elicited data showing that, within 
this sample of African American survivors of lung cancer, despite significant physical 
symptom burden and depressive symptoms, these participants were thankful to have the 
ability to live and fight for another day and therefore felt their QOL was adequate. They 
also expressed that judgement from others did not have a bearing on how they felt about 
themselves even though there were regrets about their health behavior decisions. This 
response is positive and an adaptive response to perceived stigma of shame and blame 
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(Hamann, et al., 2014). This is essential evidence regarding coping with lung cancer 
stigma.  
 Despite that the African Americans reported a higher QOL, the survival rates 
remain dismally lower for this population (American Cancer Society [ACS], 2016).  
Disparity among African American survivors of lung cancer can be attributed to 
diagnosis at later stages of cancer with metastasis, higher symptom burden, and higher 
levels of depressive symptoms (ACS, 2016; Traeger, Cannon, Pirl, & Park, 2013). 
Lathan, Waldman, Browning, Gagne, and Emmons (2015) reported in their qualitative 
study that African American survivors of lung cancer expressed that the disparity they 
experience is a result of race and quality of care. Interestingly, participants in this study 
expressed their lack of trust and lack of fair treatment from insurance companies and 
employers. They expressed that both entities’ treatment stemmed from financial gain 
and/or loss. Lung cancer stigma can be reflective of perceived discrimination not only for 
society but also from established entities such as insurance providers and employers. This 
was an interesting finding among these participants.  
Social isolation was described by many participants. This isolation was associated 
with physical symptoms and depressive symptoms. So despite the higher level of QOL, 
this population of survivors of lung cancer experience lung cancer stigma as indicated by 
discrimination, social isolation, and the responsibility of cigarette smoking. However, the 
shame associated with stigma was not indicated through the qualitative data.   
Quantitative Data: Chapter Four 
The quantitative data of the study evaluated the entire sample in chapter 4. 
Internal consistency reliability for the entire sample was .96, which was also excellent. 
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The same finding relative to construct validity was reported with the entire sample, for 
both African Americans and Caucasians survivors of lung cancer. The levels of stigma, 
depression, and QOL were important to evaluate for comparison to give indication of 
difference and insight on the possible effect of the association of these constructs. African 
Americans reported experiencing lung cancer stigma at a higher level than their 
Caucasian counterparts. Depression also was reported at a higher level among African 
American then Caucasians. Surprisingly, African Americans reported a higher QOL than 
Caucasians in the study. The latter was an unexpected finding. However, the qualitative 
part of the study, in chapter 3, assisted with understanding this finding. Another 
important notable finding was that race was significantly related to lung cancer stigma 
and that African Americans had a higher adjusted level of stigma than Caucasians. In 
fact, the findings indicated that, after adjusting for demographic characteristics 
(educational attainment, gender, smoking status, work status, time of diagnosis, marital 
status, and self-reported health status), African Americans’ stigma scores were an 
average of 10 to 11 points higher than those of Caucasians. This was a statistically 
significant finding. Income was also a statistically significant factor, with lower annual 
household incomes associated with higher levels of stigma experienced by the lung 
cancer survivors. This addresses a gap in the literature and will add to the body of 
knowledge of lung cancer.   
Clinical Implications 
Survivors of lung cancer live with tremendous physical symptom burden and 
psychological distress, which lead to social isolation and lower overall QOL 
(encompassing physical, mental, and social well-being). It is difficult to differentiate 
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causation of these challenges due to their interrelation. It is important, however, that 
health professionals acknowledge and have awareness of the presence of lung cancer 
stigma and of its negative ramifications for overall QOL. A holistic assessment approach 
including physical, psychological, and social well-being of survivors of lung cancer is 
warranted to develop appropriate individualized care planning and treatment. In addition, 
survivors should be assessed for psychological distresses, such as depression and anxiety 
stemming from socioeconomic-related needs. Doing so should assist with further 
investigation into the relationships of these distresses with stigma, and their ability to 
compound existing psychological and social challenges, thus increasing physical 
symptom burden to perpetuate a vicious cycle.  
Research Implications 
Despite improvements in public awareness of lung cancer, stigma persists. Future 
research focuses should include public perception of lung cancer stigma and 
incorporation of tailored public awareness of lung cancer stigma. As evidence has 
indicated, it is difficult to change public perception; myriad efforts and many years may 
be necessary (Public Agenda, 2016). Health communication research can direct these 
efforts and propel them forward. Just as important, research should be pursued that 
focuses on developing interventions that will decrease the negative effects of stigma on 
those living with lung cancer. Disparities related to lung cancer warrant further 
investigation, including evaluation of depression among all living with lung cancer, 
particularly African Americans. Specifically, investigation should focus on medical 
providers’ recognition and treatment of depressive symptoms in this vulnerable 
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population, as well as on health communication with this group concerning depression 
education.  
Conclusion  
The major strength of this research is that it generated new evidence related to 
lung cancer survivors in South Carolina and contributed to the body of knowledge about 
African American lung cancer survivors. As described earlier, a second strength was the 
nearly equal representation of African Americans in the study. The third strength was the 
multiple-method approach, which provided rich qualitative data that deepened 
understanding of lung cancer stigma and validated the quantitative data. However, the 
sample size was smaller than desired and represented only a small region of the United 
States, thereby limiting the ability to generalize the findings. The researchers involved in 
this study desire to continue investigating survivors of lung cancer among all vulnerable 
populations and throughout all regions of the United States, in both rural and 
metropolitan areas. In addition to these future research goals, investigating cultural 
considerations such as understanding and interpretation of the CLCSS is warranted 
among a geographically diverse group of African Americans survivors of lung cancer. 
 
 
 
 
 
  
116 
REFERENCES 
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., . . . de 
Haes, J.C. (1993). The European Organization for Research and Treatment of 
Cancer QLQ-C30: A quality-of-life instrument for use in international clinical 
trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. 
American Cancer Society. (2016). Cancer facts and figures for African Americans 2016–
2018. Retrieved from https://www.cancer.org/content/dam/cancer-
org/research/cancer-facts-and-statistics/cancer-facts-and-figures-for-african-
americans/cancer-facts-and-figures-for-african-americans-2016-2018.pdf   
American Cancer Society. (2018). Cancer facts and figures 2018. Retrieved from 
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-
statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf  
American Cancer Society. (2019). Cancer facts and figures 2019. Retrieved from 
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-
statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf 
American Lung Association. (2014). Addressing the stigma of lung cancer. Retrieved 
from https://www.lung.org/assets/documents/research/addressing-the-stigma-of-
lung-cancer.pdf  
American Lung Association. (2018). Retrieved from http://www.lung.org/our-
initiatives/tobacco/reports-resources/sotc/state-grades/highlights.html 
117 
American Lung Association. (2019). Lung cancer fact sheet. Retrieved from 
https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/lung-
cancer/resource-library/lung-cancer-fact-sheet.html 
Arksey, H., & O’Malley, L. (2005). Scoping studies: Towards a methodological 
framework. International Journal of Social Research Methodology, 8(1), 19–32. 
http://dx.doi.org/10.1080/1364557032000119616 
Bayer, R. (2008). Stigma and the ethics of public health: Not can we but should we. 
Social Science & Medicine, 67(3), 463–472. 
http://dx.doi.org/10.1016/j.socscimed.2008.03.017 
Berger, B. E., Ferrans, C. E., & Lashley, F. R. (2001). Measuring stigma in people with  
HIV: Psychometric assessment of the HIV stigma scale. Research in Nursing & 
Health, 24(6), 518–529. http://dx.doi.org/10.1002/nur.10011 
Brown, C., & Cataldo, J. (2013). Explorations of lung cancer stigma for female long-term 
survivors. Nursing Inquiry, 20(4), 352–362. http://dx.doi.org/10.1111/nin.12024 
Brown-Johnson, C. G., Brodsky, J. L., & Cataldo, J. K. (2014). Lung cancer stigma, 
anxiety, depression, and quality of life. Journal of Psychosocial Oncology, 32(1), 
59–73. http://dx.doi.org/10.1080/07347332.2013.855963 
Brown-Johnson, C. G., Cataldo, J. K., Orozco, N., Lisha, N. E., Hickman, N. J., & 
Prochaska, J. J. (2015). Validity and reliability of the internalized stigma of 
smoking inventory: An exploration of shame, isolation, and discrimination in 
smokers with mental health diagnoses. American Journal on Addictions, 24(5), 
410–418. http://dx.doi.org/10.1111/ajad.12215 
118 
Buseh, A. G., Kelber, S. T., Hewitt, J. B., Stevens, P. E., & Park, C. G. (2006). Perceived 
stigma and life satisfaction: Experiences of urban African American men living 
with HIV/AIDS. International Journal of Men’s Health, 5(1), 35–51. 
doi:10.3149/jmh.0501.35 
Carter-Harris, L., & Hall, L. A. (2014). Development of a short version of the Cataldo 
Lung Cancer Stigma Scale. Journal of Psychosocial Oncology, 32(6), 665–677. 
doi:10.1080/07347332.2014.955238 
Carter-Harris, L., Hermann, C. P., Schreiber, J., Weaver, M. T., & Rawl, S. M. (2014). 
Lung cancer stigma predicts timing of medical help-seeking behavior. Oncology 
Nursing Forum, 41(3), E203–E210. doi:10.1188/14.ONF.E203-E210 
Cataldo, J. K., Jahan, T. M., & Pongquan, V. L. (2012). Lung cancer stigma, depression, 
and quality of life among ever and never smokers. European Journal of Oncology 
Nursing, 16(3), 264–269. http://dx.doi.org/10.1016/j.ejon.2011.06.008 
Cataldo, J. K., Slaughter, R., Jahan, T. M., Pongquan, V. L., & Hwang, W. J. (2011). 
Measuring stigma in people with lung cancer: Psychometric testing of the Cataldo 
Lung Cancer Stigma Scale. Oncology Nursing Forum, 38(1), E46–E54. 
http://dx.doi.org/10.1188/11.ONF.E46-E54 
Centers for Disease Control and Prevention. (2018). U.S. cancer statistics: Data 
visualizations. Retrieved from https://gis.cdc.gov/Cancer/USCS/DataViz.html 
Chambers, S. K., Baade, P., Youl, P., Aitken, J., Occhipinti, S., Vinod, S., . . . O’Connell, 
D. L. (2015). Psychological distress and quality of life in lung cancer: The role of 
health-related stigma, illness appraisals and social constraints. Psycho-Oncology, 
24(11), 1569–1577. doi:10.1002/pon.3829 
119 
Chambers, S. K., Dunn, J., Occhipinti, S., Hughes, S., Baade, P., Sinclair, S., . . . 
O’Connell, D. L. (2012). A systematic review of the impact of stigma and 
nihilism on lung cancer outcomes. BMC Cancer, 12(1), 184.  
http://dx.doi.org/10.1186/1471-2407-12-184 
Chambers, S. K., Morris, B. A., Clutton, S., Foley, E., Giles, L., Schofield, P., . . . Dunn, 
J. (2015). Psychological wellness and health-related stigma: A pilot study of an 
acceptance-focused cognitive behavioural intervention for people with lung 
cancer. European Journal of Cancer Care, 24(1), 60–70. 
http://dx.doi.org/10.1111/ecc.12221 
Chapple, A., Ziebland, S., & McPherson, A. (2004, June 17). Stigma, shame, and blame 
experienced by patients with lung cancer: Qualitative study. BMJ. 
http://dx.doi.org/ doi:10.1136/bmj.38111.639734.7C 
Creswell, J. W. (2013). Qualitative Inquiry and Research Design, 3rd ed. Los Angeles:  
Sage.  
Criswell, K. R., Owen, J. E., Thornton, A. A., & Stanton, A. L. (2016). Personal 
responsibility, regret, and medical stigma among individuals living with lung 
cancer. Journal of Behavioral Medicine, 39(2), 241–253.  
http://dx.doi.org/10.1007/s10865-015-9686-6 
Coughlin, S. S., Matthews-Juarez, P., Juarez, P. D., Melton, C. E., & King, M. (2014). 
Opportunities to address lung cancer disparities among African Americans. 
Cancer Medicine, 3(6), 1467–1476. doi:10.1002/cam4.348 
Daher, M. (2012). Cultural beliefs and values in cancer patients [Supplement 3]. Annals 
of Oncology, 23, 66–69. http://dx.doi.org/10.1093/annonc/mds091 
120 
de Moor, J. S., Mariotto, A. B., Parry, C., Alfano, C. M., Padgett, L., Kent, E. E., . . . 
Rowland, J. H. (2013). Cancer survivors in the United States: Prevalence across 
the survivorship trajectory and implications for care. Cancer Epidemiology, 
Biomarkers & Prevention, 22(4), 561–570. http://dx.doi.org/10.1158/1055-
9965.epi-12-1356 
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011). Lung cancer: Epidemiology, 
etiology, and prevention. Clinical Chest Medicine, (32)4, 605–644.  
https://doi.org/10.1016/j.ccm.2011.09.001 
Depoy E., & Gitlin, L. N. (2011). Introduction to research: Understanding and applying 
multiple strategies (4th ed.). Elsevier Mosby: St. Louis, MO. 
Dixit, N., Crawford, G. B., Lemonde, M., Rittenberg, C. N., & Fernández-Ortega, P. 
(2016). Left behind: Cancer disparities in the developed world. Supportive Care 
in Cancer, 24(8), 3261–3264. doi:10.1007/s00520-016-3192-4 
Else-Quest, N. M., LoConte, N. K., Schiller, J. H., & Hyde, J. S. (2009). Perceived 
stigma, self-blame, and adjustment among lung, breast and prostate cancer 
patients. Psychology and Health, 24(8), 949–964. 
doi:10.1080/08870440802074664 
Fetters, M. D., Curry, L. A., & Creswell, J. W. (2013). Achieving integration in mixed 
methods designs—principles and practices. Health Services Research, 48(6, pt. 
2), 2134–2156. https://doi.org/10.1111/1475-6773.12117 
Fife, B. L., & Wright, E. R. (2000). The dimensionality of stigma: A comparison of its 
impact on the self of persons with HIV/AIDS and cancer. Journal of Health and 
Social Behavior, 41(1), 50–67. http://dx.doi.org/10.2307/2676360 
121 
Fiteni, F., Vernerey, D., Bonnetain, F., Vaylet, F., Sennélart, H., Trédaniel, J., . . . 
Westeel, V. (2016). Prognostic value of health-related quality of life for overall 
survival in elderly non-small-cell lung cancer patients. European Journal of 
Cancer, 52, 120–128. doi:10.1016/j.ejca.2015.10.004 
Gielen, A. C., & Green, L. W. (2015). The impact of policy, environmental, and 
educational interventions: A synthesis of the evidence from two public health 
success stories. Health Education and Behavior, 42(Suppl. 1), 20s–34s. 
doi:10.1177/1090198115570049 
Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. New York, 
NY: Touchstone Publishing. 
Gonzalez, B. D., & Jacobsen, P. B. (2012). Depression in lung cancer patients: The role 
of perceived stigma. Psycho-Oncology, 21(3), 239–246. 
http://dx.doi.org/10.1002/pon.1882 
Gonzalez, B. D., Jim, H. S. L., Cessna, J. M., Small, B. J., Sutton, S. K., & Jacobsen, P. 
B. (2015). Concealment of lung cancer diagnosis: Prevalence and correlates. 
Psycho-Oncology, 24(12), 1774–1783. http://dx.doi.org/10.1002/pon.3793 
Grove, S. K., Burns, N., & Gray, J. R. (2013). Practice of nursing research: Appraisal, 
synthesis, and generation of evidence (7th ed.). St. Louis, MO: Elsevier/Saunders. 
Hamann, H. A., Ostroff, J. S., Marks, E. G., Gerber, D. E., Schiller, J. H., & Lee, S. J. C. 
(2014). Stigma among patients with lung cancer: A patient-reported measurement 
model. Psycho-Oncology, 23(1), 81–92. http://dx.doi.org/10.1002/pon.3371 
Hamann, H. A., Shen, M. J., Thomas, A. J., Lee, S. J. C., & Ostroff, J. S. (2017). 
Development and preliminary psychometric evaluation of a patient-reported 
122 
outcome measure for lung cancer stigma. Stigma and Health, 3(3), 195–203. 
http://dx.doi.org/10.1037/sah0000089 
Houlihan, N.G., & Tyson, L.B. (2012). Lung Cancer (2nd ed.). Oncology Nursing 
Society: Pittsburgh, PA. 
Institute of Medicine. (2013, September 10). Delivering high-quality cancer care: 
Charting a new course for a system in crisis. The National Academies Press: 
Washington, DC. https://doi.org/10.17226/18359 
Institute of Medicine and National Research Council (2006). From cancer patient to 
cancer survivor: Lost in transition. The National Academies Press: Washington, 
DC. https://doi.org/10.17226/11468 
Jeong, J. Y., Jeong, G., & So, H. S. (2016). How do lung cancer patients experience 
stigma?: A meta-synthesis of qualitative studies. Korean Journal of Adult 
Nursing, 28(1), 116–126. doi:10.7475/kjan.2016.28.1.116 
Kissane, D. W., Patel, S. G., Baser, R.E., Bell, R., Farberov, M., Ostroff, J. S., . . . Shah, 
J. P. (2013). Preliminary evaluation of the reliability and validity of the Shame 
and Stigma Scale in head and neck cancer. Head and Neck, 35(2), 172–183. 
doi:10.1002/hed.22943 
Lathan, C. S., Waldman, L. T., Browning, E., Gagne, J., & Emmons, K. (2015). 
Perspectives of African Americans on lung cancer: A qualitative analysis. 
Oncologist, 20(4), 393–399. doi:10.1634/theoncologist.2014-0399 
Lebel, S., Castonguay, M., Mackness, G., Irish, J., Bezjak, A., & Devins, G. M. (2013). 
The psychosocial impact of stigma in people with head and neck or lung cancer. 
Psycho-Oncology, 22(1), 140–152. http://dx.doi.org/ 10.1002/pon.2063 
123 
Lebel, S., Feldstain, A., McCallum, M., Beattie, S., Irish, J., Bezjak, A., & Devins, G. M. 
(2013). Do behavioural self-blame and stigma predict positive health changes in 
survivors of lung or head and neck cancers? Psychology and Health, 28(9), 1066–
1081. doi:10.1080/08870446.2013.781602 
Lehto, R. H. (2014). Patient views on smoking, lung cancer, and stigma: A focus group 
perspective. European Journal of Oncology Nursing, 18(3), 316–322. 
http://dx.doi.org/10.1016/j.ejon.2014.02.003 
Levi-Minzi, M. A., & Surratt, H. L. (2014). HIV stigma among substance abusing people 
living with HIV/AIDS: Implications for HIV treatment. AIDS Patient Care & 
STDS, 28(8), 442–451. doi:10.1089/apc.2014.0076 
Liu, H., Yang, Q., Narsavage, G. L., Yang, C., Chen, Y., Xu, G., & Wu, X. (2016). 
Coping with stigma: The experiences of Chinese patients living with lung cancer. 
SpringerPlus, 5(1), 1790. doi:10.1186/s40064-016-3486-5 
LoConte, N. K., Else-Quest, N. M., Eickhoff, J., Hyde, J., & Schiller, J. H. (2008). 
Assessment of guilt and shame in patients with non-small-cell lung cancer 
compared with patients with breast and prostate cancer. Clinical Lung Cancer, 
9(3), 171–178. doi:10.3816/CLC.2008.n.026 
McDonnell, K. K., Owens, O. L., Hilfinger Messias, D. K., Heiney, S. P., Friedman, D. 
B., Campbell, C., & Webb, L. A. (2019). Health behavior changes in African 
American family members facing lung cancer: Tensions and compromises. 
European Journal of Oncology Nursing, 38, 57–64. 
https://doi.org/10.1016/j.ejon.2018.12.002 
124 
Montazeri, A. (2009). Quality of life data as prognostic indicators of survival in cancer 
patients: An overview of the literature from 1982 to 2008. Health and Quality of 
Life Outcomes, 7(102), 1–21. doi:10.1186/1477-7525-7-102 
Nicklasson, M., & Bergman, B. (2007). Validity, reliability and clinical relevance of 
EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative 
setting. Quality of Life Research, 16(6), 1019–1028.  
doi:10.1007/s11136-007-9210-8 
Park, E. R., Japuntich, S. J., Traeger, L., Cannon, S., Pajolek, H. (2011). Disparities 
between Black and Whites in tabacco and lung cancer treatment. Oncologist, 
16(10), 1428-1434. Doi:10.1634/theoncologist.2011-0114 
Peretti-Watel, P., Legleye, S., Guignard, R., & Beck, F. (2014). Cigarette smoking as a 
stigma: Evidence from France. International Journal of Drug Policy, 25(2), 282–
290. doi:10.1016/j.drugpo.2013.08.009 
Peters, M. D. J., Godfrey, C. M., Khalil, H., McInerney, P., Parker, D., & Soares, C. B. 
(2015). Guidance for conducting systematic scoping reviews. International 
Journal of Evidence-Based Healthcare, 13(3), 141–146. 
doi:10.1097/XEB.0000000000000050 
Pew Research Center. (2017). Numbers, facts and trends shaping your world: U.S. survey 
research; Sampling. Retrieved from http://www.pewresearch.org/methodology/u-
s-survey-research/sampling/ 
Polit, D. F., & Beck, C. T. (2008). Nursing research: Generating and assessing evidence 
for nursing practice (8th ed.). Philadelphia, PA: Walters Kluwer/Lippincott 
Williams & Wilkins. 
125 
Public Agenda. (2016). The seven stages of public opinion. Retrieved from 
https://www.publicagenda.org/pages/seven-stages-public-opinion 
Quinn, D. M., Weisz, B. M., & Lawner, E. K. (2017). Impact of active concealment of 
stigmatized identities on physical and psychological quality of life. Social Science 
and Medicine, 192, 14–17. doi.org/10.1016/j.socscimed.2017.09.024 
Radloff, L. S. (1977). The CES-D Scale: A self-report depression scale for research in the 
general population. Applied Psychological Measurement, 1(3), 385–401. 
https://doi.org/10.1177/014662167700100306 
Rauma, V., Sintonen, H., Räsänen, J. V., Salo, J. A., & Ilonen, I. K. (2015). Long-term 
lung cancer survivors have permanently decreased quality of life after surgery. 
Clinical Lung Cancer, 16(1), 40–45 46p. doi:10.1016/j.cllc.2014.08.004 
Rowland, C., Danson, S. J., Rowe, R., Merrick, H., Woll, P. J., Hatton, M. Q., . . . Eiser, 
C. (2016). Quality of life, support and smoking in advanced lung cancer patients: 
A qualitative study. BMJ Supportive & Palliative Care, 6(1), 35–42. 
doi:10.1136/bmjspcare-2013-000589 
Sandelowski, M., & Barroso, J. (2007). Handbook for synthesizing qualitative research. 
New York, NY: Springer. 
Scott, N., Crane, M., Lafontaine, M., Seale, H., & Currow, D. (2015). Stigma as a barrier 
to diagnosis of lung cancer: Patient and general practitioner perspectives. Primary 
Health Care Research and Development, 16(6), 618–622. 
doi:10.1017/S1463423615000043 
126 
Shen, M. J., Hamann, H. A., Thomas, A. J., & Ostroff, J. S. (2016). Association between 
patient-provider communication and lung cancer stigma. Supportive Care in 
Cancer, 24(5), 2093–2099. doi:10.1007/s00520-015-3014-0 
Shen, M. J., Coups, E. J., Li, Y., Holland, J. C., Hamann, H. A., & Ostroff, J. S. (2015). 
The role of posttraumatic growth and timing of quitting smoking as moderators of 
the relationship between stigma and psychological distress among lung cancer 
survivors who are former smokers. Psycho-Oncology, 24(6), 683–690. 
http://dx.doi.org/10.1002/pon.3711 
Singh, G. K., & Jemal, A. (2017). Socioeconomic and racial/ethnic disparities in cancer 
mortality, incidence, and survival in the United States, 1950–2014: Over six 
decades of changing patterns and widening inequalities. Journal of Environmental 
and Public Health, 2017, article ID 2819372. 
https://doi.org/10.1155/2017/2819372 
So, H. S., Chae, M. J., & Kim, H. Y. (2017). Reliability and validity of the Korean 
version of the Cancer Stigma Scale. Journal of Korean Academy Nursing, 47(1), 
121–132. doi:10.4040/jkan.2017.47.1.121 
Tod, A. M., Craven, J., & Allmark, P. (2008). Diagnostic delay in lung cancer: A 
qualitative study. Journal of Advanced Nursing, 61(3), 336–343. 
doi:10.1111/j.1365-2648.2007.04542.x 
Traeger, L., Cannon, S., Pirl, W. F., & Park, E. R. (2013). Depression and undertreatment 
of depression: Potential risks and outcomes in black patients with lung cancer. 
Journal of Psychosocial Oncology, 31(2), 123–135. 
doi:10.1080/07347332.2012.761320 
127 
U.S. Department of Health and Human Services. (2019). Poverty guidelines. Retrieved 
from https://aspe.hhs.gov/poverty-guidelines 
U.S. Department of Health and Human Services Public Health Office of the Surgeon 
General. (1964). Smoking and health: Report of the advisory committee to the 
surgeon general of the Public Health Service. Retrieved from 
https://profiles.nlm.nih.gov/ps/access/NNBBMQ.pdf  
U.S. Department of Health and Human Services Public Health Office of the Surgeon 
General. (2014). The health consequences of smoking—50 years of progress: A 
report of the surgeon general. Retrieved from 
http://www.surgeongeneral.gov/library/reports/50-years-of-progress/exec-
summary.pdf 
United States Census Bureau. (2017). QuickFacts: South Carolina. Retrieved from 
https://www.census.gov/quickfacts/SC 
Webb, L. A., & McDonnell, K. K. (2018). Not a death sentence: Perspectives of African 
American women living with lung cancer. Oncology Nursing Forum, 45(1), 46–
54. doi:10.1188/18.ONF.46-54 
Weiss, J., Yang, H., Weiss, S., Rigney, M., Copeland, A., King, J. C., & Deal, A. M. 
(2016). Stigma, self-blame, and satisfaction with care among patients with lung 
cancer. Journal of Psychosocial Oncology, 35(2), 166–179. 
doi:10.1080/07347332.2016.1228095 
World Health Organization. (2017). Constitution of WHO: Principles. Retrieved from 
http://www.who.int/about/mission/en 
128 
Yang, Q., Liu, H., Yang, C., Ji, S., & Li, L. (2014). Reliability and validity of Chinese 
version of Cataldo Lung Cancer Stigma Scale. International Journal of Nursing 
Sciences, 1(1), 23–27. https://doi.org/10.1016/j.ijnss.2014.02.011 
 
  
129 
APPENDIX A:  
THE CATALDO LUNG CANCER STIGMA SCALE (CLCSS), FULL AND SHORT 
VERSIONS, PLUS PERMISSION TO USE 
130 
Cataldo Lung Cancer Stigma Scale 
Instructions:  Below is a list of statements dealing with your general feelings about 
yourself.  If you strongly agree, circle SA.  If you agree with the statement, circle A. If 
you disagree, circle D.  If you strongly disagree, circle SD.   
 Strongly 
Agree 
Agree Disagree Strongly 
Disagree 
1.  I feel guilty because I have 
lung cancer. 
 
1 
 
2 
 
3 
 
4 
2.  People with lung cancer 
lose jobs when employers 
learn. 
 
1 
 
2 
 
3 
 
4 
3. I work hard to keep my lung 
cancer a secret. 
 
1 
 
2 
 
3 
 
4 
4. I feel I’m not as good as 
others because I have lung 
cancer. 
 
1 
 
2 
 
3 
 
4 
5.  People with lung cancer are 
treated like outcasts.   
 
1 
 
2 
 
3 
 
4 
6.       Most people believe a 
person with lung cancer is 
dirty. 
 
1 
 
2 
 
3 
 
4 
7. Having lung cancer makes 
me feel unclean. 
 
1 
 
2 
 
3 
 
4 
8.  I feel set apart, isolated 
from the rest of the word.  
 
1 
 
2 
 
3 
 
4 
9. Having lung cancer makes 
me feel like I’m a bad 
person. 
 
1 
 
2 
 
3 
 
4 
10. Some people who know 
have grown more distant. 
 
1 
 
2 
 
3 
 
4 
131 
11. I worry about people 
discriminating against me. 
 
1 
 
2 
 
3 
 
4 
12. Most are uncomfortable 
around someone with lung 
cancer. 
 
1 
 
2 
 
3 
 
4 
13. I feel the need to hide the 
fact I have lung cancer.  
 
1 
 
2 
 
3 
 
4 
14. I worry that people may 
judge me when they learn I 
have lung cancer. 
 
1 
 
2 
 
3 
 
4 
15. I was hurt how people 
reacted to learning I have 
lung cancer. 
 
1 
 
2 
 
3 
 
4 
16. People I care about stopped 
calling after learning. 
 
1 
 
2 
 
3 
 
4 
17. Some told me lung cancer is 
what I deserved for 
smoking. 
 
1 
 
2 
 
3 
 
4 
18. People have physically 
backed away from me. 
 
1 
 
2 
 
3 
 
4 
19. Some people think it is my 
fault I have lung cancer. 
 
1 
 
2 
 
3 
 
4 
20. Stopped socializing with 
some due to their reactions. 
 
1 
 
2 
 
3 
 
4 
21. Have lost friends by telling 
them I have lung cancer. 
 
1 
 
2 
 
3 
 
4 
22. People seem afraid of me 
because I have lung cancer. 
 
1 
 
2 
 
3 
 
4 
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Thank you for completing the Lung Cancer Stigma Scale. 
  
23. Older people are less likely 
than young people to be 
blamed for having lung 
cancer. 
 
1 
 
2 
 
3 
 
4 
24. Healthcare providers don’t 
take “smoker’s cough 
seriously”.  
 
1 
 
2 
 
3 
 
4 
25. People avoid you because 
lung cancer is associated 
with death. 
 
1 
 
2 
 
3 
 
4 
26. My lung cancer diagnosis 
was delayed because my 
health care provider did not 
take my “smoker’s cough” 
seriously. 
 
1 
 
2 
 
3 
 
4 
27. I put off going to the doctor 
because I was afraid. 
 
1 
 
2 
 
3 
 
4 
28. Smokers could be refused 
treatment for lung cancer. 
 
1 
 
2 
 
3 
 
4 
29. Others assume that a 
patient’s lung cancer was 
caused by smoking even if 
he or she had stopped 
smoking years ago. 
 
1 
 
2 
 
3 
 
4 
30. Others assume that a 
patient’s lung cancer was 
caused by smoking even if 
he or she never smoked. 
 
1 
 
2 
 
3 
 
4 
31. Lung cancer is viewed as a 
self-inflicted disease.  
 
1 
 
2 
 
3 
 
4 
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11-Item Scale 
Below is a list of statements dealing with your general feelings about yourself.  If you 
strongly agree, circle SA.  If you agree with the statement, circle A. If you disagree, 
circle D.  If you strongly disagree, circle SD.   
 
Strongly 
Agree 
Agree Disagree 
Strongly 
Disagree 
1. I feel guilty because I have 
lung cancer. 
1 2 3 4 
2.  Some people assume that a 
person’s lung cancer was 
caused by smoking, even if 
he or she never smoked. 
1 2 3 4 
3. I try to keep my lung cancer 
a secret. 
1 2 3 4 
4. Some people are 
uncomfortable around me 
because they associate lung 
cancer with death. 
1 2 3 4 
5. I worry that people may 
judge me because I have 
lung cancer. 
1 2 3 4 
6. Some people believe lung 
cancer is what I deserve. 
1 2 3 4 
7. Some people act like it is 
my fault I have lung cancer. 
1 2 3 4 
8. I stopped socializing with 
some people because of 
their reactions to my lung 
cancer diagnosis. 
1 2 3 4 
9. I worry about people 
discriminating against me. 
1 2 3 4 
10. Some health care providers 
would treat me better if I 
had a different kind of 
cancer. 
1 2 3 4 
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11. Lung cancer is viewed as a 
self-inflicted disease. 
1 2 3 4 
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APPENDIX C:  
THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF 
CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30 (EORTC QLQ-30) 
139 
 
140 
 
 
141 
 
  
142 
APPENDIX D:  
DEMOGRAPHIC INFORMATION FORM 
143 
 
Information Form 
        Study ID #:__________ 
        Date: ______________ 
 
 
Instructions:  Please provide some background information about yourself by circling the 
best response or filling in the blank.  Thank you.  
 
1. What year were you born?    ________________ 
 
2. Are you male or female? ___________________ 
 
3. What is your race ? 
 
A. Caucasian   
B. Black or Afro-American 
C. Latino (Puerto Rican, Cuban, Dominican etc.) 
D. West Indian (Haitian, Jamaican etc.) 
E. Oriental or Asian American 
F. Native American 
G. Other 
 
4. What is your marital status? 
A. Single (never married) 
B. Seperated or divorced (not living with a husband/wife) 
C. Married (living with a husband/wife/significant friend) 
D. Widowed 
 
5. What is the highest grade or year of school you complete? 
A. Never attended school or only attended kindergarten 
B. Grades 1 through 8 (Elementary) 
C. Grades 9 through 11 (Some high school) 
D. Grade 12 or GEC (High school graduate) 
E. College 1 year to 3 years (Some college or technical school) 
F. College 4 years or more (College graduate) 
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6. Are currently . . . 
A. Employed for wages 
B. Self-employed 
C. Out of work for 1 year or more 
D. Out of work for less than 1 year 
E. A Homemaker 
F. A Student 
G. Retired 
H. Unable to work 
 
7. What is the annual income of your household? 
A. $4,999 or less 
B. $5,000-$9,999 
C. $10,000-$19,999 
D. $20,000-$49,000 
E. $50,000-$99,000 
F. $100,000 or more 
 
8. Would you say that in general your health is: 
A. Excellent 
B. Very good 
C. Good 
D. Fair 
E. Poor 
 
9. In what year were you first told that you had lung cancer? 
A. 2016 
B. 2015 
C. 2014 
D. 2013 
E. 2012 
F. 2011 
G. 2010 
 
10. Have you smoked at least 100 cigarettes in your entire life? (5 packs = 100 
cigarettes) 
A. Yes 
B. No 
C. Not at all 
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11. Do you now smoke cigarettes? 
A. Everyday 
B. Some days 
C. Not at all 
 
12. For how many years did you smoke regularly?  _______________ 
 
13. If you do not currently smoke cigarettes but did in the past, how long has it been 
since you last smoke regularly? (example every day or some days) 
 
A. Within the past month (0-1 month ago) 
B. Within the past 3 months (1-3 months ago) 
C. Within the past 6 months (3-6 months ago) 
D. Within the past year (6-12 months ago) 
E. Within the past 5 years (1-5 years ago) 
F. Within the past 15 years (5-15 years ago) 
G. More than 15 or more years ago 
H. Don’t know/Not sure 
I. Never smoked regularly 
 
14. On average, about how many cigarettes a day do or did you smoke? (1 pack = 20 
cigarettes) __________cigarettes. 
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